臨床循環器学

出版社： 文光堂
著者：
発行日： 2021-03-16
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784830619670
電子書籍版： 2021-03-16 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する
特記事項：
  • 【電子書籍】著作権者の意向により電子版では非掲載の画像がございます

商品紹介

“これ一冊で循環器学の全てがわかる”，スタンダードを押さえつつ進歩の波に呑まれない，循環器学の教科書が誕生！病態の知識，診断・治療法を始めとして，糖尿病・慢性腎臓病などの他臓器疾患の合併や，成人先天性心疾患・腫瘍循環器学などの新たな領域まで幅広く網羅し，実臨床に活かせるプラクティカルな視点での解説も盛り込んだ．循環器学を志す全ての人へ，循環器学を総合的・体系的に学べる必携の一冊．

目次

  • 第1章　循環器疾患の新潮流
    　A　変わる疾病構造と迫られる対応
    　B　根拠ある診療とは
    　C　個別化医療・先制医療
    　D　医療の質のたゆまぬ向上を目指して
    　E　チーム医療：心不全
    　F　臓器連関
    　G　腸内細菌叢と循環器疾患
    　H　求められる医療倫理
    　I　地域連携の実際
    　J　緩和医療

    第2章　心不全
    　A　心不全の疫学と病型
    　B　心不全の病態生理
    　C　心不全の分子生物学的機序
    　D　心不全の診断
    　E　急性心不全
    　F　HFrEFの診療
    　G　HFpEFの診療
    　H　非薬物治療：内科的治療
    　I　非薬物治療：外科手術
    　J　重症心不全（ステージD）

    第3章　不整脈・心臓突然死
    　A　不整脈の機序
    　B　不整脈の診断とリスク層別化 　
    　C　上室性不整脈
    　D　心房細動
    　E　心室期外収縮・心室頻拍
    　F　遺伝性不整脈
    　G　徐脈性不整脈
    　H　デバイスの調整と管理，合併症
    　I　失神と心臓突然死

    第4章　動脈硬化性・炎症性疾患
    　A　動脈硬化の機序
    　B　脂質代謝の正常と異常
    　C　動脈硬化のスクリーニング
    　D　安定冠動脈疾患
    　E　ST上昇型心筋梗塞
    　F　非ST上昇型急性冠症候群
    　G　冠動脈インターベンション（PCI）
    　H　大動脈瘤
    　I　大動脈解離
    　J　高安動脈炎

    第5章　末梢血管疾患
    　A　末梢動脈硬化症
    　B　その他の血管疾患
    　C　脳卒中
    　D　静脈血栓塞栓症

    第6章　心臓弁膜症
    　A　心臓弁膜症の疫学
    　B　心臓弁膜症の診断
    　C　僧帽弁閉鎖不全症
    　D　僧帽弁狭窄症
    　E　大動脈弁閉鎖不全症
    　F　大動脈弁狭窄症
    　G　三尖弁疾患・肺動脈弁疾患
    　H　人工弁
    　I　感染性心内膜炎

    第7章　心筋疾患・心膜疾患
    　A　拡張型心筋症
    　B　肥大型心筋症
    　C　不整脈原性右室心筋症
    　D　拘束型心筋症
    　E　周産期心筋症
    　F　心臓サルコイドーシス
    　G　心アミロイドーシス
    　H　化学物質による心筋障害
    　I　心筋炎
    　J　心膜炎・心囊液貯留
    　K　心臓腫瘍

    第8章　肺高血圧症
    　A　肺高血圧症の定義・分類・診断
    　B　肺動脈性肺高血圧症
    　C　左心性心疾患に伴う肺高血圧症
    　D　結合組織病に伴う肺高血圧症
    　E　慢性血栓塞栓性肺高血圧症

    第9章　成人先天性心疾患
    　A　成人先天性心疾患の疫学と課題
    　B　Fallot四徴症
    　C　心房中隔欠損症・卵円孔開存症
    　D　心室中隔欠損症
    　E　修正大血管転位
    　F　Fontan循環
    　G　川崎病
    　H　チアノーゼを呈する成人先天性心疾患
    　I　成人先天性心疾患患者の妊娠と出産

    第10章　腫瘍循環器学
    　A　腫瘍循環器学の定義と課題
    　B　がん治療関連による心機能障害・不整脈
    　C　がん治療関連による血管障害
    　D　がんに伴う血栓塞栓症

    第11章　生活習慣と心疾患
    　A　2型糖尿病
    　B　高血圧
    　C　脂質異常症
    　D　現代人における栄養摂取の問題
    　E　スポーツと心疾患
    　F　喫　煙
    　G　貧　血
    　H　心臓リハビリテーション

    第12章　特定患者の心疾患
    　A　高齢者
    　B　女性と妊娠
    　C　循環器疾患を持つ非心臓手術患者の管理

    第13章　他臓器疾患による心血管疾患
    　A　内分泌異常と心疾患
    　B　神経筋疾患と心疾患
    　C　自律神経と心疾患
    　D　凝固異常症
    　E　慢性腎臓病

    第14章　診察と検査
    　A　病歴と身体診察
    　B　心電図
    　C　心エコー図
    　D　血管エコー
    　E　胸部単純X線
    　F　MDCT
    　G　核医学検査・PET
    　H　MRI
    　I　カテーテル検査
    　J　冠動脈内画像診断法
    　K　心筋生検
    　L　心肺運動負荷試験

    第15章　臨床研究を実施する
    　A　臨床研究の計画
    　B　臨床試験のエビデンスの解釈

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 循環器疾患の新潮流

P.5 掲載の参考文献
1) Omran, AR : The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q 49 : 509-538, 1971
PubMed
2) Olshanksy, SJ et al : The fourth stage of the epidemiologic transition : the age of delayed degenerative diseases. Milbank Q 64 : 355-391, 1986
 
3) 橋本修二 : 健康寿命の指標化に関する研究 (健康日本21 (第二次) 等の健康寿命の検討). 厚生労働科学研究費補助金 (循環器疾患・糖尿病等生活習慣病対策総合研究事業) 分担研究報告書, 26-38, 2016
 
4) Ejiri, K et al : Unprecedented crisis-Heart failure hospitalization in current or future Japan. J Cardiol 74 : 426-427, 2019
PubMed
P.9 掲載の参考文献
1) Sackett, DL et al : Evidence based medicine : what it is and what it isn't. BMJ 312 : 71-72, 1996
 
2) 中山健夫 : 「他領域からのトピックス」臨床研究から診療ガイドラインへ : 根拠に基づく医療 (EBM) の原点から. 日耳鼻 113 : 93-100, 2010
 
3) Guyatt, GH : Evidence-based medicine. ACP J Club 114 : A16, 1991
 
4) Haynes, RB et al : Physicians' and patients' choices in evidence based practice. BMJ 324 : 1350, 2002
PubMed
5) Murad, MH et al : New evidence pyramid. Evid Based Med 21 : 125-127, 2016
PubMed
6) McGlynn, EA et al : The quality of health care delivered to adults in the United States. N Engl J Med 348 : 2635-2645, 2003
PubMed
7) Graham, R et al eds : Clinical Practice Guidelines We Can Trust, National Academies Press, Washington DC, 2011
 
8) 小島原典子ほか編 : Minds診療ガイドライン作成マニュアル 2017, 公益財団法人日本医療機能評価機構 EBM医療情報部, 2017
 
9) 日本循環器学会 : 急性冠症候群ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_kimura.pdf (2020年10月閲覧)
 
10) Eddy, DM : Clinical decision making : from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263 : 3077, 3081, 3084, 1990
 
P.14 掲載の参考文献
1) Ho, CY et al : Genotype and lifetime burden of disease in hypertrophic cardiomyopathy : Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138 : 1387-1398, 2018
PubMed
2) Haggerty, CM et al : Genomics-first evaluation of heart disease associated with titin-truncating variants. Circulation 140 : 42-54, 2019
PubMed
3) Robertson, J et al : Higher body mass index in adolescence predicts cardiomyopathy risk in midlife. Circulation 140 : 117-125, 2019
PubMed
4) Morita, H : Human genomics in cardiovascular medicine : implications and perspectives. Circ J 77 : 876-885, 2013
PubMed
5) Khera, AV et al : Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. Circulation 139 : 1593-1602, 2019
PubMed
6) Ko, T et al : Quantification of DNA damage in heart tissue as a novel prediction tool for therapeutic prognosis of patients with dilated cardiomyopathy. JACC Basic Transl Sci 4 : 670-680, 2019
PubMed
7) Natarajan, P et al : Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135 : 2091-2101, 2017
PubMed
P.19 掲載の参考文献
1) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction : ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2 : 349-360, 1988
 
2) Fonarow, GC et al : Improving evidence-based care for heart failure in outpatient cardiology practices : primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 122 : 585-596, 2010
PubMed
3) Fonarow, GC et al : Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure : A nested case-control analysis of IMPROVE HF. J Am Heart Assoc 1 : 16-26, 2012
 
4) Kinugasa, Y et al : Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res 14 : 351, 2014
 
5) Okumura, Y et al : Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation-Findings from the SAKURA AF Registry. Circ J 82 : 2500-2509, 2018
PubMed
6) Szummer, K et al : Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments : experiences from the SWEDEHEART registry 1995-2014. Eur Heart J 38 : 3056-3065, 2017
PubMed
7) Yasuda, S et al : Current status of cardiovascular medicine in the aging society of Japan. Circulation 138 : 965-967, 2018
PubMed
P.24 掲載の参考文献
1) 日本心不全学会 : 高齢心不全患者の治療に関するステートメント. 2016, http://www.asas.or.jp/jhfs/pdf/Statement_HeartFailurel.pdf (2020年1月閲覧)
 
2) Yaku, H et al : Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan-observations from the prospective, multicenter Kyoto Congestive Heart Failure (KCHF) registry. Circ J 82 : 2811-2819, 2018
PubMed
3) McAlister, FA et al : A systematic review of randomized trials of disease management programs in heart failure. Am J Med 110 : 378-384, 2001
PubMed
4) Kinugasa, Y et al : Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res 14 : 351, 2014
 
5) 佐藤幸人 : 心不全の基礎知識 100, 第2版, 東京, 文光堂, 2019
 
6) 日本看護協会 : 認定看護師教育基準カリキュラム (分野 : 慢性心不全看護. 平成31年4月改正). https://nintei.nurse.or.jp/nursing/wp-content/uploads/2019/05/21mannseisinnhuzenn_A_20190513.pdf (2020年1月閲覧)
 
7) 山田佐登美ほか : 慢性心不全看護認定看護師 (仮) とは. ハートナーシング 23 : 86-89, 2010
Medical*Online
8) Koshman, SL et al : Pharmacist care of patients with heart failure : a systematic review of randomized trials. Arch Intern Med 168 : 687-694, 2008
PubMed
9) 日本心不全学会 : 心不全患者における栄養評価・管理に関するステートメント. 2018, http://www.asas.or.jp/jhfs/pdf/statement20181012.pdf (2020年1月閲覧)
 
10) Kamiya, K et al : Nationwide survey of multidisciplinary care and cardiac rehabilitation for patients with heart failure in Japan-an analysis of the AMED-CHF study. Circ J 83 : 1546-1552, 2019
PubMed
11) Dickstein, K : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29 : 2388-2442, 2008
 
12) Tsuji, S et al : Nutritional status of outpatients with chronic stable heart failure based on serum amino acid concentration. J Cardiol 72 : 458-465, 2018
PubMed
13) Bonilla-Palomas, JL et al : Nutritional intervention in malnourished hospitalized patients with heart failure. Arch Med Res 47 : 535-540, 2016
PubMed
14) Kuragaichi, T et al : Nationwide survey of palliative care for patients with heart failure in Japan. Circ J 82 : 1336-1343, 2018
PubMed
15) Gilstrap, LG et al : An unintended consequence of the 21st-Century Cures Act for patients with heart failure. Circulation 136 : 123-125, 2017
PubMed
P.29 掲載の参考文献
1) Osborn, JW et al : Renal nerves and long-term control of arterial pressure. Compr Physiol 7 : 263-320, 2017
PubMed
2) Kiuchi, MG et al : Renal denervation update from the International Sympathetic Nervous System Summit : JACC State-of-the-Art Review. J Am Coll Cardiol 73 : 3006-3017, 2019
PubMed
3) Fujiu, K et al : A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation. Nat Med 23 : 611-622, 2017
PubMed
4) Shinohara, K et al : Circulating angiotensin II deteriorates left ventricular function with sympathoexcitation via brain angiotensin II receptor. Physiol Rep 3 : e12514, 2015
 
5) Sigmund, CD et al : No brain renin-angiotensin system : Deja vu all over again? Hypertension 69 : 1007-1010, 2017
PubMed
6) Shinohara, K et al : Selective deletion of the brain-specific isoform of renin causes neurogenic hypertension. Hypertension 68 : 1385-1392, 2016
PubMed
7) Matsuura, T et al : Prior exposure to placental ischemia causes increased salt sensitivity of blood pressure via vasopressin production and secretion in postpartum rats. J Hypertens 37 : 1657-1667, 2019
PubMed
8) Iyonaga, T et al : Brain perivascular macrophages contribute to the development of hypertension in stroke-prone spontaneously hypertensive rats via sympathetic activation. Hypertens Res 43 : 99-110, 2020
 
9) Katsuki, M et al : Decreased proportion of Foxp3+ CD4+ regulatory T cells contributes to the development of hypertension in genetically hypertensive rats. J Hypertens 33 : 773-783, 2015
 
P.33 掲載の参考文献
1) Arumugam, M et al : Enterotypes of the human gut microbiome. Nature 473 : 174-180, 2011
PubMed
2) Emoto, T et al : Analysis of gut microbiota in coronary artery disease patients : A possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb 23 : 908-921, 2016
PubMed
3) Jie, Z et al : The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 8 : 845, 2017
PubMed
4) Yoshida, N et al : Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation 138 : 2486-2498, 2018
PubMed
5) Wang, Z et al : Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 : 57-63, 2011
PubMed
6) Wang, Z et al : Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163 : 1585-1595, 2015
PubMed
7) Tang, WH et al : Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure : refining the gut hypothesis. J Am Coll Cardiol 64 : 1908-1914, 2014
PubMed
8) Hayashi, T et al : Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure. Circ J 83 : 182-192, 2018
PubMed
9) Depommier, C et al : Supplementation with Akkermansia muciniphila in overweight and obese human volunteers : a proof-of-concept exploratory study. Nat Med 25 : 1096-1103, 2019
PubMed
P.37 掲載の参考文献
1) 河瀬雅紀 : 医療者-患者関係. 生命倫理と医療倫理, 改訂第3版, 伏木信次ほか編, 金芳堂, 京都, 20-29, 2014
 
2) 伊藤道哉 : 告知, インフォームドコンセント. 生命と医療の倫理学, 第2版, 丸善出版, 東京, 16-25, 2013
 
3) 星野一正 : いまなぜ医療の倫理か. 医療の倫理, 岩波書店, 東京, 22-40, 1991
 
4) 日本医学会 : 医療における遺伝学的検査・診断に関するガイドライン. 2011, http://jams.med.or.jp/guideline/genetics-diagnosis.pdf (2020年1月閲覧)
 
P.41 掲載の参考文献
1) Feltner, C et al : Transitional care interventions to prevent readmissions for persons with heart failure : a systematic review and meta-analysis. Ann Intern Med 160 : 774-784, 2014
PubMed
2) Koehler, F et al : Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2) : a randomised, controlled, parallel-group, unmasked trial. Lancet 392 : 1047-1057, 2018
PubMed
3) Kamiya, K et al : Nationwide survey of multidisciplinary care and cardiac rehabilitation for patients with heart failure in Japan-An analysis of the AMED-CHF study. Circ J 83 : 1546-1552, 2019
PubMed
4) Allen, LA et al : Decision making in advanced heart failure : a scientific statement from the American Heart Association. Circulation 125 : 1928-1952, 2012
PubMed
5) Canepa, M et al : Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail 6 : 452-462, 2018
 
6) Rodriguez-Pascual, C et al : Comprehensive geriatric assessment and hospital mortality among older adults with decompensated heart failure. Am Heart J 164 : 756-762, 2012
PubMed
7) Quinn, KL et al : Association between palliative care and healthcare outcomes among adults with terminal non-cancer illness : population based matched cohort study. BMJ 370 : m2257, 2020
PubMed
8) Chaudhry, SI et al : Telemonitoring in patients with heart failure. N Engl J Med 363 : 2301-2309, 2010
PubMed
9) Koehler, F et al : Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure : study design. Eur J Heart Fail 12 : 1354-1362, 2010
PubMed
10) Ong, MK et al : Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure : the Better Effectiveness After Transition-Heart Failure (BEAT-HF) randomized clinical trial. JAMA Intern Med 176 : 310-318, 2016
PubMed
P.48 掲載の参考文献
1) Anzai, T et al : Effect on short-term prognosis and left ventricular function of angina pectoris prior to first Q-wave anterior wall acute myocardial infarction. Am J Cardiol 74 : 755-759, 1994
PubMed
2) Allen, LA et al : Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 299 : 2533-2542, 2008
PubMed
3) Rose, EA et al : Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 : 1435-1443, 2001
PubMed
4) Swetz, KM et al : Preparedness planning before mechanical circulatory support : a "how-to" guide for palliative medicine clinicians. J Pain Symptom Manage 47 : 926-935.e6, 2014
 
5) Warraich, HJ et al : Characteristics and trends among patients with cardiovascular disease referred to palliative care. JAMA Netw Open 2 : e192375, 2019
PubMed
6) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
7) Detering, KM et al : The impact of advance care planning on end of life care in elderly patients : randomised controlled trial. BMJ 340 : c1345, 2010
PubMed
8) Allen, LA et al : Decision making in advanced heart failure : a scientific statement from the American Heart Association. Circulation 125 : 1928-1952, 2012
PubMed
9) Murray, S et al : Using the 'surprise question' can identify people with advanced heart failure and COPD who would benefit from a palliative care approach. Palliat Med 25 : 382, 2011
PubMed
10) Straw, S et al : Predicting one-year mortality in heart failure using the 'Surprise Question' : a prospective pilot study. Eur J Heart Fail 21 : 227-234, 2019
PubMed
11) Hamatani, Y et al : Survey of palliative sedation at end of life in terminally ill heart failure patients-A single-center experience of 5-year follow-up. Circ J 83 : 1607-1611, 2019
PubMed

第2章 心不全

P.54 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
2) 日本循環器学会 : 循環器疾患診療実態調査 2018年報告書 (2019年度実施・公表). http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2018web.pdf (2020年10月閲覧)
 
3) Lindenfeld, J et al : HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16 : e1-e194, 2010
PubMed
4) Shimokawa, H et al : Heart failure as a general pandemic in Asia. Eur J Heart Fail 17 : 884-892, 2015
 
5) Owan, TE et al : Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 : 251-259, 2006
PubMed
6) Tsuji, K et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction -a report from the CHART-2 study. Eur J Heart Fail 19 : 1258-1269, 2017
 
7) Adams, KF Jr et al : Characteristics and outcomes of patients hospitalized for heart failure in the United States : rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 : 209-216, 2005
 
8) Kajimoto, K et al : Gender differences in anemia and survival in patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction. Am J Cardiol 120 : 435-442, 2017
PubMed
9) Sakata Y, et al : Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. Circ J 78 : 428-435, 2014
 
10) Tsuchihashi-Makaya, M et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009
PubMed
11) Pitt, B et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014
PubMed
12) Solomon, SD et al : Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381 : 1609-1620, 2019
PubMed
13) Forrester, JS et al : Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 295 : 1404-1413, 1976
PubMed
14) Nohria, A et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003
PubMed
15) Mebazaa, A et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-S139, 2008
PubMed
16) Yancy, CW et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-e327, 2013
 
17) Ponikowski, P et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 : 891-975, 2016
 
P.59 掲載の参考文献
1) Hall, JE ed : Guyton and Hall Textbook of Medical Physiology, 11th ed, Elsevier Saunders, Philadelphia, 2006
 
2) 大西勝也 : カテーテル時代に知っておきたい新しい心血行動態入門 いちから学びたい人にDr.大西から80のクエスチョン, メディカ出版, 大阪, 2014
 
3) Hall, JE : Integration and regulation of cardiovascular function. Am J Physiol 277 : S174-S186, 1999
PubMed
4) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
5) Zipes, DP et al eds : Braunwald's heart disease -A Textbook of Cardiovascular Medicine, 11th ed, Elsevier, Philadelphia, 2019
 
6) Gheorghiade, M et al : Assessing and grading congestion in acute heart failure : a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12 : 423-433, 2010
 
7) Fallick, C et al : Sympathetically mediated changes in capacitance : redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 4 : 669-675, 2011
PubMed
P.67 掲載の参考文献
1) Louch, WE et al : No rest for the weary : diastolic calcium homeostasis in the normal and failing myocardium. Physiology (Bethesda) 27 : 308-323, 2012
PubMed
2) Schlotthauer, K et al : Sarcoplasmic reticulum Ca (2+) release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ Res 87 : 774-780, 2000
PubMed
3) Garfinkel, AC et al : Genetic pathogenesis of hypertrophic and dilated cardiomyopathy. Heart Fail Clin 14 : 139-146, 2018
PubMed
4) Miyata, S et al : Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 86 : 386-390, 2000
PubMed
5) Sheikh, F et al : Mouse and computational models link Mlc2v dephosphorylation to altered myosin kinetics in early cardiac disease. J Clin Invest 122 : 1209-1221, 2012
PubMed
6) Scruggs, SB et al : A novel, in-solution separation of endogenous cardiac sarcomeric proteins and identification of distinct charged variants of regulatory light chain. Mol Cell Proteomics 9 : 1804-1818, 2010
PubMed
7) Torre-Amione, G et al : Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction : a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 27 : 1201-1206, 1996
PubMed
8) Shyu, KG et al : Cyclic stretch enhances the expression of toll-like receptor 4 gene in cultured cardiomyocytes via p38 MAP kinase and NF-κB pathway. J Biomed Sci 17 : 15, 2010
 
9) Nakai, A et al : The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13 : 619-624, 2007
PubMed
10) Oka, T et al : Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485 : 251-255, 2012
PubMed
11) Ueda, H et al : Administration of a TLR9 inhibitor attenuates the development and progression of heart failure in mice. JACC Basic Transl Sci 4 : 348-363, 2019
PubMed
12) Mann, DL et al : Targeted anticytokine therapy in patients with chronic heart failure : results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 : 1594-1602, 2004
PubMed
13) Everett, BM et al : Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation 139 : 1289-1299, 2019
PubMed
14) Torre-Amione, G et al : Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial) : a placebo-controlled randomised trial. Lancet 371 : 228-236, 2008
 
P.76 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
2) Stevenson, LW et al : The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261 : 884-888, 1989
PubMed
3) Edwards, P et al : Both diastolic and systolic function alternate in pulsus alternans : a case report and review. J Am Soc Echocardiogr 16 : 695-697, 2003
PubMed
4) McKee, PA et al : The natural history of congestive heart failure : the Framingham study. N Engl J Med 285 : 1441-1446, 1971
PubMed
5) Forrester, JS et al : Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 295 : 1404-1413, 1976
PubMed
6) Nohria, A et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003
PubMed
7) Mebazaa, A et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-S139, 2008
PubMed
8) Weber, M et al : Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92 : 843-849, 2006
PubMed
9) 日本心不全学会 : 血中BNPやNT-proBNP値を用いた心不全診療の留意点について. http://www.asas.or.jp/jhfs/topics/bnp201300403.html (2020年1月閲覧)
 
10) Pfisterer, M et al : BNP-guided vs symptom-guided heart failure therapy : the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 : 383-392, 2009
PubMed
11) Sato, N et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013
PubMed
12) Inohara, T et al : Prognostic impact of renal dysfunction does not differ according to the clinical profiles of patients : insight from the acute decompensated heart failure syndromes (ATTEND) registry. PLoS One 9 : e105596, 2014
 
13) Mullens, W et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 : 589-596, 2009
PubMed
14) Takahama, H et al : Pathophysiology of cardiorenal syndrome in patients with heart failure : potential therapeutic targets. Am J Physiol Heart Circ Physiol 313 : H715-H721, 2017
PubMed
15) Tsang, TS et al : Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90 : 1284-1289, 2002
 
16) Nagueh, SF et al : Recommendations for the evaluation of left ventricular diastolic function by echocardiography : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 17 : 1321-1360, 2016
PubMed
17) Andersen, OS et al : Estimating left ventricular filling pressure by echocardiography. J Am Coll Cardiol 69 : 1937-1948, 2017
PubMed
P.83 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
2) Green, SM et al : Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 168 : 741-748, 2008
PubMed
3) Gheorghiade, M et al : Assessing and grading congestion in acute heart failure : a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12 : 423-433, 2010
 
4) Stevenson, LW et al : The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261 : 884-888, 1989
PubMed
5) Jensen, MB et al : Transthoracic echocardiography for cardiopulmonary monitoring in intensive care. Eur J Anaesthesiol 21 : 700-707, 2004
PubMed
6) Spencer, KT et al : Focused cardiac ultrasound : recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 26 : 567-581, 2013
PubMed
7) Enghard, P et al : Simplified lung ultrasound protocol shows excellent prediction of extravascular lung water in ventilated intensive care patients. Crit Care 19 : 36, 2015
 
8) Mebazaa, A et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-S139, 2008
PubMed
9) Nohria, A et al : Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 96 : 32G-40G, 2005
PubMed
10) Kajimoto K et al : Relationship between systolic blood pressure and preserved or reduced ejection fraction at admission in patients hospitalized for acute heart failure syndromes. Int J Cardiol 168 : 4790-4795, 2013
PubMed
11) Cotter, G et al : Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 : 389-393, 1998
PubMed
12) Clark, AL et al : In-hospital worsening heart failure : a clinically relevant endpoint? ESC Heart Fail 5 : 9-18, 2018
PubMed
P.98 掲載の参考文献
1) Yancy, CW et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-e327, 2013
 
2) Ponikowski, P et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 : 891-975, 2016
 
3) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
4) Tsuchihashi-Makaya, M et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009
PubMed
5) McKee, PA et al : The natural history of congestive heart failure : the Framingham study. N Engl J Med 285 : 1441-1446, 1971
PubMed
6) Mancini, DM et al : Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83 : 778-786, 1991
PubMed
7) 日本循環器学会 : 2016年版 心臓移植に関する提言. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_isobe_h.pdf (2020年10月閲覧)
 
8) Greulich, S et al : CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 6 : 501-511, 2013
PubMed
9) Assomull, RG et al : Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 : 1977-1985, 2006
PubMed
10) 吉田幸彦ほか : 高度房室ブロック症例における心サルコイドーシスの頻度について. 心臓 27 : 874-880,1995
Medical*Online
11) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf (2020年10月閲覧)
 
12) 心筋生検研究会編 : 診断モダリティとしての心筋病理, 南江堂, 東京, 2017年
 
13) O'Keefe, JH Jr et al : Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Cardiol 7 : 3-7, 2000
 
14) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (2020年10月閲覧)
 
P.108 掲載の参考文献
1) Steinberg, BA et al : Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction : prevalence, therapies, and outcomes. Circulation 126 : 65-75, 2012
PubMed
2) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pd (2020年10月閲覧)
 
3) Owan, TE et al : Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 : 251-259, 2006
PubMed
4) Shah, SJ et al : Phenotype-specific treatment of heart failure with preserved ejection fraction : A multiorgan roadmap. Circulation 134 : 73-90, 2016
PubMed
5) Kao, DP et al : Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 17 : 925-935, 2015
PubMed
6) Nagai, T et al : Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction -A report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J 82 : 1534-1545, 2018
PubMed
7) Pieske, B et al : How to diagnose heart failure with preserved ejection fraction : the HFA-PEFF diagnostic algorithm : a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40 : 3297-3317, 2019
 
8) Cleland, JG et al : The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 : 2338-2345, 2006
PubMed
9) Yusuf, S et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 : 777-781, 2003
PubMed
10) Massie, BM et al : Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 : 2456-2467, 2008
PubMed
11) Pitt, B et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014
PubMed
12) Yamamoto, K et al : Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 : 110-118, 2013
 
13) Solomon, SD et al : Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381 : 1609-1620, 2019
PubMed
14) Kinugasa, Y et al : The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction. Heart 103 : 184-189, 2017
PubMed
15) Pandey, A et al : Exercise training in patients with heart failure and preserved ejection fraction : meta-analysis of randomized control trials. Circ Heart Fail 8 : 33-40, 2015
PubMed
16) Kinugasa, Y et al : Home-based inspiratory muscle training in patients with heart failure and preserved ejection fraction : a preliminary study. J Card Fail 26 : 1022-1023, 2020
PubMed
17) Kinugasa, Y et al : Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res 14 : 351, 2014
 
P.117 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
2) 渡邊英一ほか : 不整脈に起因する失神例の運転免許取得に関する診断書作成と適性検査施行の合同検討委員会ステートメント 改訂のための補遺 3. http://new.jhrs.or.jp/pdf/guideline/statement201708_02.pdf (2020年1月閲覧)
 
3) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf (2020年10月閲覧)
 
4) Normand, C et al : Indications for cardiac resynchronization therapy : a comparison of the major international guidelines. JACC Heart Fail 6 : 308-316, 2018
PubMed
5) Kotecha, D et al : Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 384 : 2235-2243, 2014
 
6) Marrouche, NF et al : Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378 : 417-427, 2018
PubMed
7) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告) 循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2010momomura.h.pdf (2020年10月閲覧)
 
8) 日本循環器学会 : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2012/11/JCS2012_Nohara.pdf (2020年10月閲覧)
 
9) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 
10) Adamson, PB : Pathophysiology of the transition from chronic compensated and acute decompensated heart failure : new insights from continuous monitoring devices. Curr Heart Fail Rep 6 : 287-292, 2009
PubMed
P.122 掲載の参考文献
1) Jessup, M et al : Heart failure. N Engl J Med 348 : 2007-2018, 2003
PubMed
2) Bonow, RO et al : Severity of remodeling, myocardial viability, and survival in ischemic LV dysfunction after surgical revascularization. JACC Cardiovasc Imaging 8 : 1121-1129, 2015
PubMed
3) Alderman, EL et al : Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 82 : 1629-1646, 1990
PubMed
4) Yusuf, S et al : Effect of coronary artery bypass graft surgery on survival : Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344 : 563-570, 1994
PubMed
5) Velazquez, EJ et al : Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374 : 1511-1520, 2016
PubMed
6) Marui, A et al : Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions < 50% versus > 50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol 114 : 988-996, 2014
PubMed
7) Iribarne, A et al : Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world Surgical Treatment for Ischemic Heart Failure trial population. J Thorac Cardiovasc Surg 156 : 1410-1421.e2, 2018
 
8) Dor, V : Left ventricular aneurysms : the endoventricular circular patch plasty. Semin Thorac Cardiovasc Surg 9 : 123-130, 1997
PubMed
9) Isomura, T et al : Septal anterior ventricular exclusion operation (Pacopexy) for ischemic dilated cardiomyopathy : treat form not disease. Eur J Cardiothorac Surg 29 : S245-S250, 2006
 
10) Matsui, Y et al : Overlapping cardiac volume reduction operation. J Thorac Cardiovasc Surg 124 : 395-397, 2002
PubMed
11) Dor, V et al : Late hemodynamic results after left ventricular patch repair associated with coronary grafting in patients with postinfarction akinetic or dyskinetic aneurysm of the left ventricle. J Thorac Cardiovasc Surg 110 : 1291-1299 ; discussion 1300-1301, 1995
 
12) Athanasuleas, CL et al : Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 44 : 1439-1445, 2004
PubMed
13) Jones, RH et al : Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 360 : 1705-1717, 2009
 
P.130 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
2) Imamura, T et al : Is the internal jugular vein or femoral vein a better approach site for endomyocardial biopsy in heart transplant recipients? Int Heart J 56 : 67-72, 2015
 
3) Imamura, T et al : Is cardiopulmonary exercise testing essential to indicate ventricular assist device implantation in patients with INTERMACS profile 4-7? J Artif Organs 19 : 226-232, 2016
 
4) Kirklin, JK et al : INTERMACS database for durable devices for circulatory support : first annual report. J Heart Lung Transplant 27 : 1065-1072, 2008
PubMed
5) Imamura, T et al : Improvement in biventricular cardiac function after ambulatory counterpulsation. J Card Fail 25 : 20-26, 2019
PubMed
6) Imamura, T et al : Status 2 patients had poor prognosis without mechanical circulatory support. Circ J 78 : 1396-1404, 2014
PubMed
7) Imamura, T et al : Omega-3 therapy is associated with reduced gastrointestinal bleeding in patients with continuous-flow left ventricular assist device. Circ Heart Fail 11 : e005082, 2018
PubMed

第3章 不整脈・心臓突然死

P.137 掲載の参考文献
1) 日本循環器学会 : 遺伝性不整脈の診療に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_aonuma_h.pdf (2020年1月閲覧)
 
2) Sanguinetti, MC et al : hERG potassium channels and cardiac arrhythmia. Nature 440 : 463-469, 2006
PubMed
3) Priori, SG et al : HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10 : 1932-1963, 2013
PubMed
4) Schwartz, PJ et al : Long-QT syndrome : from genetics to management. Circ Arrhythm Electrophysiol 5 : 868-877, 2012
PubMed
5) Brugada, P et al : Right bundle branch block, persistent ST segment elevation and sudden cardiac death : a distinct clinical and electrocardiographic syndrome : A multicenter report. J Am Coll Cardiol 20 : 1391-1396, 1992
PubMed
6) Gussak, I et al : Idiopathic short QT interval : a new clinical syndrome? Cardiology 94 : 99-102, 2000
PubMed
P.146 掲載の参考文献
1) Steinberg, JS et al : 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm 14 : e55-e96, 2017
PubMed
2) Kennedy, HL : Use of long-term (Holter) electrocardiographic recording. Cardiac Electrophysiology : From Cell to Bedside, 3rd ed, Zipes, DP et al eds, WB Saunders, Philadelphia, 716-730, 2000
 
3) Zimetbaum, P et al : Ambulatory arrhythmia monitoring : choosing the right device. Circulation 122 : 1629-1636, 2010
PubMed
4) Balady, GJ et al : Exercise Testing. Braunwald's Heart Disease : A Textbook of Cardiovascular Medecine, 10th ed, Mann, DL et al eds, Elsevier, Philadelphia, 155-178, 2015
 
5) Priori, SG et al : HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10 : 1932-1963, 2013
PubMed
6) Priori, SG et al : 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36 : 2793-2867, 2015
 
7) Al-Khatib, SM et al : 2017 AHA/ACC/HRS guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : executive summary : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138 : e210-e271, 2018
 
8) Berbari, EJ et al : The methods of recording and analysis of the signal averaged ECG. Signal Averaged Electrocardiography : Concepts, Methods and Applications, Gomes, JA ed, Kluwer Academic Publishers, Dordecht, 49-68, 1993
 
9) Verrier, RL et al : Microvolt T-wave alternans : Physiological basis, methods of measurement, and clinical utility : Consensus guideline by the International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol 58 : 1309-1324, 2011
 
P.159 掲載の参考文献
1) Page, RL et al : 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia : A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 133 : e506-e574, 2016
 
2) Brugada, P et al : A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 83 : 1649-1659, 1991
 
3) Katritsis, DG et al : Catheter ablation of atypical atrioventricular nodal reentrant tachycardia. Circulation 134 : 1655-1663, 2016
PubMed
4) Heidbuchel, H et al : Catheterization of subforms of AV nodal reentrant tachycardia. Europace 6 : 316-329, 2004
 
5) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (2020年10月閲覧)
 
6) Natale, A et al : Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 35 : 1898-1904, 2000
PubMed
7) Bastani, H et al : Cryothermal vs. radiofrequency ablation as atrial flutter therapy : a randomized comparison. Europace 15 : 420-428, 2013
PubMed
8) Rahman, F et al : Atrial flutter : Clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm 13 : 233-240, 2016
PubMed
9) Busch, S et al : Acute and long-term outcome of focal atrial tachycardia ablation in the real world : results of the german ablation registry. Clin Res Cardiol 107 : 430-436, 2018
PubMed
10) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami191120.pdf (2020年10月閲覧)
 
P.169 掲載の参考文献
1) Inoue, H et al : Prevalence of atrial fibrillation in the general population of Japan : an analysis based on periodic health examination. Int J Cardiol 137 : 102-107, 2009
PubMed
2) Chugh, SS et al : Worldwide epidemiology of atrial fibrillation : a Grobal Burden of Disease 2010 study. Circulation 129 : 837-847, 2014
 
3) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (2020年10月閲覧)
 
4) Gage, BF et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 285 : 2864-2870, 2001
 
5) Camm, AJ et al : European Heart Rhythm Association ; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 : 2369-2429, 2010
 
6) Lip, GYH et al : Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the euro heart survey on atrial fibrillation. Chest 137 : 263-272, 2009
 
7) Suzuki, S et al : Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Resistry, and Fushimi AF Registry. Circ J 79 : 432-438, 2015
 
8) Pisters, R et al : A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey. Chest 138 : 1093-1100, 2010
PubMed
9) 日本脳卒中学会 : 植込み型心電図記録計の適応となり得る潜因性脳梗塞患者の診断の手引き. 2016, https://www.jsts.gr.jp/img/tebiki_noukousoku.pdf (2020年1月閲覧)
 
10) Olshansky, B et al : The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study : approach to control rate in atrial fibrillation. J Am Coll Cardiol 43 : 1201-1208, 2004
 
11) Van Gelder, IC et al : Lenient versus strict rate control in patients with atrial fibrillation. N Eng J Med 362 : 1363-1373, 2010
 
12) Ogawa, S et al : Optimal treatment strategy for patients with paroxysmal atrial fibrillation : J-Rhythm Study. Circ J 73 : 242-248, 2009
 
13) Endo, A et al : Impact of drug alteration to maintain rhythm control in paroxysmal atrial fibrillation-Subanalysis from J-RHYTHM study-. Circ J 74 : 870-875, 2010
 
14) Hsu, LF et al : Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351 : 2373-2383, 2004
PubMed
15) Di Biase, L et al : Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device : Result from the AATAC multicenter randomized trial. Circulation 133 : 1637-1644, 2016
 
16) Marrouche, NF et al : Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378 : 417-427, 2018
PubMed
17) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf (2020年10月閲覧)
 
18) Calkins, H et al : 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation : Executive summary. Heart Rhythm 14 : e445-e494, 2017
PubMed
19) Verma, A et al : Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372 : 1812-1822, 2015
PubMed
20) Rienstra, M et al : Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation : results of the RACE 3 trial. Eur Heart J 39 : 2987-2996, 2018
PubMed
P.179 掲載の参考文献
1) Agarwal, SK et al : Relation of ventricular premature complexes to heart failure (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol 109 : 105-109, 2012
PubMed
2) Huizar, JF et al : Left ventricular systolic dysfunction induced by ventricular ectopy : a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol 4 : 543-549, 2011
PubMed
3) Smith, ML et al : High-frequency ventricular ectopy can increase sympathetic neural activity in humans. Heart Rhythm 7 : 497-503, 2010
PubMed
4) Kuroki, K et al : Prediction and mechanism of frequent ventricular premature contractions related to haemodynamic deterioration. Eur J Heart Fail 14 : 1112-1120, 2012
PubMed
5) Bogun, F et al : Radiofrequency ablation of frequent, idiopathic premature ventricular complexes : comparison with a control group without intervention. Heart Rhythm 4 : 863-867, 2007
PubMed
6) Yokokawa, M et al : Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 9 : 92-95, 2012
PubMed
7) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2018/07/JCS2018_kurita_nogami.pdf (2020年10月閲覧)
 
8) Daubert, JP et al : Inappropriate implantable cardioverter-defibrillator shocks in MADIT II : frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 51 : 1357-1365, 2008
PubMed
9) Sapp, JL et al : Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 375 : 111-121, 2016
PubMed
10) Santangeli, P et al : Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with imIplantable cardioverter-defibrillators : A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm 13 : 1552-1559, 2016
PubMed
P.190 掲載の参考文献
1) 清水渉 : II-7-6-4) 突然死. 内科學ASAKURA Internal Medicine, 第11版, 矢崎義雄総編集, 朝倉書店, 東京, 508-510, 2017
 
2) 清水渉 : II-7-4-3) 遺伝性不整脈. 内科學ASAKURA Internal Medicine, 第11版, 矢崎義雄総編集, 朝倉書店, 東京, 423-427, 2017
 
3) Shimizu, W et al : Association of genetic and clinical aspects of congenital long QT syndrome with life-threatening arrhythmias in Japanese patients. JAMA Cardiol 4 : 246-254, 2019
 
4) Priori, SG et al : HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart rhythm 10 : 1932-1963, 2013
PubMed
5) 日本循環器学会 : 遺伝性不整脈の診療に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_aonuma_h.pdf (2020年10月閲覧)
 
6) Schwartz, PJ et al : QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 124 : 2181-2184, 2011
 
7) Antzelevitch, C et al : J-Wave syndromes expert consensus conference report : Emerging concepts and gaps in knowledge. J Arrhythm 32 : 315-339, 2016
 
8) Yamagata, K et al : Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome : A Japanese multicenter registry. Circulation 135 : 2255-2270, 2017
PubMed
9) Haissaguerre, M et al : Sudden cardiac arrest associated with early repolarization. N Engl J Med 358 : 2016-2023, 2008
PubMed
10) Antzelevitch, C et al : J wave syndromes. Heart Rhythm 7 : 549-558, 2010
 
11) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf (2020年10月閲覧)
 
P.199 掲載の参考文献
1) 日本循環器学会 : 臨床心臓電気生理検査に関するガイドライン (2011年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2011_ogawas_h.pdf (2020年10月閲覧)
 
2) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf (2020年10月閲覧)
 
3) Reynolds, D et al : A leadless intracardiac transcatheter pacing system. N Engl J Med 374 : 533-541, 2016
 
P.205 掲載の参考文献
1) Cleland, JG et al : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 : 1539-1549, 2005
PubMed
2) Daubert, JC et al : 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure : implant and follow-up recommendations and management. Heart Rhythm 9 : 1524-1576, 2012
PubMed
3) Mullens, W et al : Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 53 : 765-773, 2009
 
4) Mullens, W et al : Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol 53 : 600-607, 2009
PubMed
5) Pappone, C et al : Improving cardiac resynchronization therapy response with multipoint left ventricular pacing : Twelve-month follow-up study. Heart Rhythm 12 : 1250-1258, 2015
PubMed
6) Birnie, D et al : Clinical outcomes with synchronized left ventricular pacing : analysis of the adaptive CRT trial. Heart Rhythm 10 : 1368-1374, 2013
PubMed
7) Haines, DE et al : Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation 123 : 2069-2076, 2011
PubMed
8) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami191120.pdf (2020年10月閲覧)
 
9) Hindricks, G et al : Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME) : a randomised controlled trial. Lancet 384 : 583-590, 2014
 
10) Hindricks, G et al : Daily remote monitoring of implantable cardioverter-defibrillators : insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST). Eur Heart J 38 : 1749-1755, 2017
PubMed
11) Nishii, N et al : Decreased intrathoracic impedance associated with OptiVol alert can diagnose increased B-type natriuretic peptide-MOMOTARO (Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization) Study. Circ J 79 : 1315-1322, 2015
PubMed
P.216 掲載の参考文献
1) Shen, WK et al : 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope : A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 70 : e39-e110, 2017
 

第4章 動脈硬化性・炎症性疾患

P.221 掲載の参考文献
1) Gimbrone, MA Jr et al : Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 118 : 620-636, 2016
PubMed
2) Bentzon, JF et al : Mechanisms of plaque formation and rupture. Circ Res 114 : 1852-1866, 2014
PubMed
3) Partida, RA et al : Plaque erosion : a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. Eur Heart J 39 : 2070-2076, 2018
 
4) Quillard, T et al : TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment : implication for superficial erosion. Eur Heart J 36 : 1394-1404, 2015
 
5) Kaikita, K et al : Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 17 : 2232-2237, 1997
PubMed
6) Matsukawa, M et al : Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 100 : 758-763, 2007
PubMed
7) Kaikita, K et al : Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 188 : 180-188, 1999
PubMed
8) Sakamoto, T et al : Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 70 : 271-276, 1992
PubMed
9) Sato, Y et al : Incidence of asymptomatic coronary thrombosis and plaque disruption : comparison of non-cardiac and cardiac deaths among autopsy cases. Thromb Res 124 : 19-23, 2009
 
P.229 掲載の参考文献
1) Yeang, C et al : 'LDL-C' =LDL-C+Lp (a) -C : implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 26 : 169-178, 2015
 
2) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防のための脂質異常症診療ガイド 2018年版. 日本動脈硬化学会, 2018
Medical*Online
3) Okamura, T et al : Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study : The Suita study. Atherosclerosis 203 : 587-592, 2009
 
4) Kitamura, A et al : High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89 : 2533-2539, 1994
PubMed
5) Rohatgi, A et al : HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371 : 2383-2393, 2014
PubMed
6) Iso, H et al : Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153 : 490-499, 2001
PubMed
7) Arsenault, BJ et al : Beyond low-density lipoprotein cholesterol : respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 55 : 35-41, 2009
PubMed
8) Anitschkow, N : Ueber die Veranderungen der Kaninchenaorta bei experimenteller Cholesterinsteatose. Beitr Pathol Anat 56 : 379-404, 1913
 
9) Dawber, TR et al : Coronary heart disease in the Framingham study. Am J Public Health Nations Health 47 : 4-24, 1957
PubMed
10) Nakamura, H et al : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006
PubMed
11) Nordestgaard BG, et al : Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population : guidance for clinicians to prevent coronary heart disease : consensus statement of the European Atherosclerosis Society. Eur Heart J 34 : 3478-3490a, 2013
PubMed
12) 塚本和久 : 脂質異常症の臨床検査. 日内会誌 102 : 3117-3124, 2013
 
13) Tsimikas, S : A test in context : lipoprotein (a) : diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69 : 692-711, 2017
PubMed
14) Tada, H et al : Lipoprotein (a) in familial hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutations. Circ J 80 : 512-518, 2016
PubMed
15) Willeit, P et al : Baseline and on-statin treatment lipoprotein (a) levels for prediction of cardiovascular events : individual patient-data meta-analysis of statin outcome trials. Lancet 392 : 1311-1320, 2018
PubMed
16) Zheng, KH et al : Lipoprotein (a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 73 : 2150-2162, 2019
PubMed
17) Tavori, H et al : Elevated lipoprotein (a) levels lower ABCA1 cholesterol efflux capacity. J Clin Endocrinol Metab 104 : 4793-4803, 2019
PubMed
18) Tsimikas, S et al : Lipoprotein (a) reduction in persons with cardiovascular disease. N Engl J Med 382 : 244-255, 2020
PubMed
P.238 掲載の参考文献
1) Virmani, R et al : Lessons from sudden coronary death : a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 : 1262-1275, 2000
 
2) Masumura, Y et al : Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy. Circ J 75 : 603-612, 2011
PubMed
3) Burke, AP et al : Healed plaque ruptures and sudden coronary death : evidence that subclinical rupture has a role in plaque progression. Circulation 103 : 934-940, 2001
 
4) Costanzo, P et al : Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials [published correction appears in J Am Coll Cardiol. 2016 Apr 5 ; 67 (13) : 1660]. J Am Coll Cardiol 56 : 2006-2020, 2010
 
5) Mohr, FW et al : Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381 : 629-638, 2013
PubMed
6) Zhang, J et al : Intravascular Ultrasound versus Angiography-Guided Drug-Eluting Stent Implantation : The ULTIMATE Trial. J Am Coll Cardiol 72 : 3126-3137, 2018
 
7) Ueda, Y et al : The healing process of infarct-related plaques : Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 38 : 1916-1922, 2001
PubMed
8) Kubo, T et al : Implication of plaque color classification for assessing plaque vulnerability : a coronary angioscopy and optical coherence tomography investigation. JACC Cardiovasc Interv 1 : 74-80, 2008
 
9) Ohtani, T et al : Number of yellow plaques detected in a coronary artery is associated with future risk of acute coronary syndrome : detection of vulnerable patients by angioscopy. J Am Coll Cardiol 47 : 2194-2200, 2006
 
10) Ueda, Y et al : In-stent yellow plaque at 1 year after implantation is associated with future event of very late stent failure : The DESNOTE Study (Detect the Event of Very late Stent Failure From the Drug-Eluting Stent Not Well Covered by Neointima Determined by Angioscopy). JACC Cardiovasc Interv 8 : 814-821, 2015
 
11) Waksman, R et al : Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging : a prospective, cohort study. Lancet 394 : 1629-1637, 2019
PubMed
P.249 掲載の参考文献
1) Osler, W : The lumleian lectures on angina pectoris. Lancet 175 : 973-977, 1910
 
2) Knuuti, J et al : 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes : The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 41 : 407-477, 2020
 
3) 日本循環器学会/日本心臓血管外科学会 : 安定冠動脈疾患の血行再建ガイドライン (2018年改訂版). http://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_nakamura_yaku.pdf (2020年10月閲覧)
 
4) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防ガイドライン 2017年版. 日本動脈硬化学会, 2017
 
5) Schroeder, S et al : Cardiac computed tomography : indications, applications, limitations, and training requirements : report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J 29 : 531-556, 2008
 
6) IONA Study Group : Effect of nicorandil on coronary events in patients with stable angina : the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359 : 1269-1275, 2002
 
7) Xie, M et al : Aspirin for primary prevention of cardiovascular events : meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One 9 : e90286, 2014
PubMed
8) 日本循環器学会 : 2020年JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf (2020年10月閲覧)
 
9) Kimura, T et al : Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation 118 : S199-S209, 2008
PubMed
10) Neumann, FJ et al : 2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 40 : 87-165, 2019
 
11) 日本循環器学会 : 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2013_ogawah_h.pdf (2020年10月閲覧)
 
12) Tsuburaya, R et al : Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation : The NOVEL study. Eur Heart J 37 : 2713-2721, 2016
PubMed
13) Knuuti, J et al : 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes : The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 41 : 407-477, 2020
 
P.257 掲載の参考文献
1) 日本循環器学会 : 急性冠症候群ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_kimura.pdf (2020年10月閲覧)
 
2) Thygesen, K et al : Fourth universal definition of myocardial infarction (2018). Eur Heart J 40 : 237-269, 2019
PubMed
3) Elgendy, IY et al : Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention : A pairwise and network meta-analysis of randomized trials. JACC Cardiovasc Interv 10 : 315-324, 2017
 
4) Lemkes, JS et al : Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med 380 : 1397-1407, 2019
PubMed
5) Villablanca, PA et al : Therapeutic hypothermia in ST elevation myocardial infarction : a systematic review and meta-analysis of randomised control trials. Heart 102 : 712-719, 2016
 
6) Thiele, H et al : Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367 : 1287-1296, 2012
PubMed
7) Ahmad, Y et al : Intra-aortic balloon pump therapy for acute myocardial infarction : A meta-analysis. JAMA Intern Med 175 : 931-939, 2015
PubMed
8) Neumann, FJ et al : 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40 : 87-165, 2019
PubMed
9) Meani, P et al : Modalities and effects of left ventricle unloading on extracorporeal life support : a review of the current literature. Eur J Heart Fail 19 : 84-91, 2017
 
10) Seyfarth, M et al : A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52 : 1584-1588, 2008
PubMed
11) Ouweneel, DM et al : Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 69 : 278-287, 2017
PubMed
12) Basir, MB et al : Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol 119 : 845-851, 2017
PubMed
13) Sauren, LDC et al : Combined Impella and intra-aortic balloon pump support to improve both ventricular unloading and coronary blood flow for myocardial recovery : an experimental study. Artif Organs 31 : 839-842, 2007
 
14) Iida, M et al : A successful case of percutaneous left ventricular assist device "Impella" to postmyocardial infarction ventricular septal perforation in Japan. Artif Organs 43 : 806-807, 2019
 
15) Knuuti, J et al : 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41 : 407-477, 2020
PubMed
P.264 掲載の参考文献
1) 日本循環器学会 : 急性冠症候群ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_kimura.pdf (2020年10月閲覧)
 
2) Amsterdam, EA et al : 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 : e139-e228, 2014
 
3) Roffi, M et al : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 : 267-315, 2016
 
4) Thygesen, K et al : Fourth universal definition of myocardial infarction (2018). Eur Heart J 40 : 237-269, 2019
PubMed
5) Daida, H et al : Management and two-year long-term clinical outcome of acute coronary syndrome in Japan : prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J 77 : 934-943, 2013
PubMed
6) Ishihara, M et al : Clinical presentation, management and outcome of Japanese patients with acute myocardial infarction in the troponin era-Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET). Circ J 79 : 1255-1262, 2015
 
7) Ishihara, M et al : Long-term outcomes of non-ST-elevation myocardial infarction without creatine kinase elevation-The J-MINUET Study. Circ J 81 : 958-965, 2017
 
8) Ibanez, B et al : 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39 : 119-177, 2018
 
9) Antman, EM et al : The TIMI risk score for unstable angina/non-ST elevation MI : A method for prognostication and therapeutic decision making. JAMA 284 : 835-842, 2000
 
10) Kosuge, M et al : Clinical implication of electrocardiograms for patients with non-ST-segment elevation acute coronary syndromes in the interventional era. Circ J 73 : 798-805, 2009
 
11) Reichlin, T et al : Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361 : 858-867, 2009
PubMed
12) Granger, CB et al : Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 : 2345-2353, 2003
PubMed
13) Fox, KA et al : Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 55 : 2435-2445, 2010
 
14) Milosevic, A et al : Immediate versus delayed invasive intervention for non-STEMI patients : The RIDDLE-NSTEMI Study. JACC Cardiovasc Interv 9 : 541-549, 2016
 
15) Quadri, G et al : Complete or incomplete coronary revascularization in patients with myocardial infarction and multivessel disease : a propensity score analysis from "real-life" BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry. Eurointervention 13 : 407-414, 2017
 
16) Sardella, G et al : Single-staged compared with multi-staged PCI in multivessel NSTEMI patients : The SMILE Trial. J Am Coll Cardiol 67 : 264-272, 2016
 
17) Watanabe, H et al : Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI : The STOPDAPT-2 Randomized Clinical Trial. JAMA 321 : 2414-2427, 2019
PubMed
18) Stone, NJ et al : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Curculation 129 : S1-S45, 2014
 
19) Catapano, AL et al : 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias : The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 37 : 2999-3058, 2016
 
20) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防ガイドライン 2017年版. 日本動脈硬化学会, 2017
 
21) Cannon, CP et al : Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 : 2387-2397, 2015
PubMed
22) Mach, F et al : 2019 ESC/EAS Guidelines for the management of dyslipidemias : lipid modification to reduce cardiovascular risk : The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41 : 111-188, 2020
 
P.279 掲載の参考文献
1) Boden, WE et al : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007
 
2) De Bruyne, B et al : Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371 : 1208-1217, 2014
PubMed
3) Tonino, PA et al : Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 : 213-224, 2009
PubMed
4) Mohr, FW et al : Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381 : 629-638, 2013
PubMed
5) 日本循環器学会/日本心臓血管外科学会 : 安定冠動脈疾患の血行再建ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_nakamura_yaku.pdf (2020年10月閲覧)
 
6) Yoshimachi, F et al : Percutaneous coronary intervention without use of guiding catheters for extreme downsizing : the Emperor's new clothes technique. Cardiovasc Interv Ther 28 : 13-215, 2013
 
7) Ormiston, JA et al : Stent longitudinal strength assessed using point compression : insights from a second-generation, clinically related bench test. Circ Cardiovasc Interv 7 : 62-69, 2014
PubMed
8) Virmani, R et al : Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent : should we be cautious? Circulation 109 : 701-705, 2004
PubMed
9) Otsuka, F et al : Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc Interv 8 : 1248-1260, 2015
 
10) Torii, S et al : Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. EuroIntervention 14 : 1685-1693, 2019
PubMed
11) Thygesen, K et al : Fourth universal definition of myocardial infarction (2018). Eur Heart J 40 : 237-269, 2019
PubMed
12) Zeitouni, M et al : Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J 39 : 1100-1109, 2018
PubMed
13) Lindsey, JB et al : Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients : results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv 2 : 1074-1082, 2009
PubMed
P.285 掲載の参考文献
1) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会 : 2020年改訂版 大動脈瘤・大動脈解離診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/07/JCS2020_Ogino.pdf (2020年10月閲覧)
 
2) Judge, DP et al : Marfan's syndrome. Lancet 366 : 1965-1976, 2005
 
3) Germain, DP : Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis 2 : 32, 2007
PubMed
4) Loeys, BL et al : A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37 : 275-281, 2005
 
5) Kasashima, S et al : Inflammatory abdominal aortic aneurysm : close relationship to IgG4-related periaortitis. Am J Surg Pathol 32 : 197-204, 2008
PubMed
6) Isselbacher, EM : Thoracic and abdominal aortic aneurysms. Circulation 111 : 816-828, 2005
PubMed
7) Gutierrez, JA et al : Polyvascular disease : reappraisal of the current clinical landscape. Circ Cardiovasc Interv 12 : e007385, 2019
PubMed
8) Hiratzka, LF et al : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121 : e266-e369, 2010
 
9) Hirsch, AT et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute ; Society for Vascular Nursing ; TransAtlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-e654, 2006
 
10) 日本胸部外科学会 : 2010年度学術調査データ (心臓分野). http://www.jpats.org/modules/investigation/index.php?content_id=15 (2020年1月閲覧)
 
P.293 掲載の参考文献
1) Hiratzka LF, et al : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121 : e266-e369, 2010
 
2) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会 : 2020年改訂版 大動脈瘤・大動脈解離診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/07/JCS2020_Ogino.pdf (2020年10月閲覧)
 
3) Erbel, R et al : 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases : Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35 : 2873-2926, 2014
 
4) Dieter, RS et al : Acute aortic syndromes : aortic dissections, penetrating aortic ulcers and intramural aortic hematomas. Expert Rev Cardiovasc Ther 3 : 423-431, 2005
PubMed
5) 吉野秀朗 : 急性大動脈解離の診断と治療に関する最新知見. 日内会誌 104 : 2031-2038, 2015
 
6) 村井達哉 : 大動脈解離と突然死-東京都監察医務院における1,320剖検例の統計的研究. 日法医会誌 42 : 564-577, 1988
 
7) Matsuda, H : Treatment of uncomplicated type B aortic dissection. Gen Thorac Cardiovasc Surg 65 : 74-79, 2017
PubMed
8) Uchida, K et al : Pathologic characteristics and surgical indications of superacute type A intramural hematoma. Ann Thorac Surg 79 : 1518-1521, 2005
PubMed
9) Eggebrecht, H et al : Retrograde ascending aortic dissection during or after thoracic aortic stent graft placement : insight from the European registry on endovascular aortic repair complications. Circulation 120 : S276-S281, 2009
 
10) Tsagakis, K et al : Hybrid operating room concept for combined diagnostics, intervention and surgery in acute type A dissection. Eur J Cardiothorac Surg 43 : 397-404, 2013
PubMed
11) Imoto, K et al : Risk analysis and improvement of strategies in patients who have acute type A aortic dissection with coronary artery dissection. Eur J Cardiothorac Surg 44 : 419-424, 2013
PubMed
12) Berretta, P et al : Malperfusion syndromes in type A aortic dissection : what we have learned from IRAD. J Vis Surg 4 : 65, 2018
PubMed
13) Tsukube, T et al : Neurological outcomes after immediate aortic repair for acute type A aortic dissection complicated by coma. Circulation 124 : S163-S167, 2011
PubMed
14) Uchida, K et al : Early reperfusion strategy improves the outcome of surgery for type A acute aortic dissection with malperfusion. J Thorac Cardiovasc Surg 156 : 483-489, 2018
 
15) Roselli, EE et al : Endovascular stent grafting for ascending aorta repair in high-risk patients. J Thorac Cardiovasc Surg 149 : 144-151, 2015
PubMed
16) Nienaber, CA et al : Endovascular repair of type B aortic dissection : long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 6 : 407-416, 2013
PubMed
17) Shimizu, H : Correction to : Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 67 : 573-575, 2019
PubMed
P.298 掲載の参考文献
1) Jennette, JC et al : 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65 : 1-11, 2013
 
2) 日本循環器学会 : 血管炎症候群の診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf (2020年10月閲覧)
 
3) Hata, A et al : Angiographic findings of Takayasu arteritis : new classification. Int J Cardiol 54 : S155-S163, 1996
PubMed
4) Yoshifuji, H : Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. Mod Rheumatol 29 : 287-293, 2019
PubMed
5) Watanabe, Y et al : Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan : Age and sex specificity. Circulation 132 : 1701-1709, 2015
PubMed
6) Maksimowicz-McKinnon, K et al : Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56 : 1000-1009, 2007
 
7) Nakaoka, Y et al : Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis : Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77 : 348-354, 2018
PubMed
8) de Souza, AW et al : Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J 74 : 1236-1241, 2010
PubMed

第5章 末梢血管疾患

P.309 掲載の参考文献
1) Ouriel, K : Peripheral arterial disease. Lancet 358 : 1257-1264, 2001
PubMed
2) Norgren, L et al : Inter-Society Consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 : S5-S67, 2007
 
3) Mills, JL Sr et al : The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System : risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 59 : 220-234.e1-e2, 2014
 
4) 日本循環器学会 : 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2015_miyata_h.pdf (2020年10月閲覧)
 
5) 日本医学放射線学会/日本腎臓学会 : 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン (第2版 : 2009年9月2日改訂). http://www.radiology.jp/content/files/649.pdf (2020年1月閲覧)
 
6) Mehler, PS et al : Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 107 : 753-756, 2003
PubMed
7) Aboyans, V et al : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by : the European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39 : 763-816, 2018
 
8) Hirsch, AT : ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute ; Society for Vascular Nursing ; TransAtlantic Inter-Society Consensus ; and Vascular Disease Foundation. J Am Coll Cardiol 47 : 1239-312, 2006
 
9) Brass, EP et al : Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 43 : 752-759, 2006
 
10) Conte, MS et al : Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 69 : 3S-125S.e40, 2019
 
11) Iida, O et al : Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia : OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up. Circ Cardiovasc Interv 6 : 68-76, 2013
PubMed
12) Iida, O et al : Prognostic impact of revascularization in poor-risk patients with critical limb ischemia : The PRIORITY registry (Poor-Risk Patients With and Without Revascularization Therapy for Critical Limb Ischemia). JACC Cardiovasc Interv 10 : 1147-1157, 2017
PubMed
13) Iida, O et al : Three-year outcomes of surgical versus endovascular revascularization for critical limb ischemia : The SPINACH Study (Surgical Reconstruction Versus Peripheral Intervention in Patients With Critical Limb Ischemia). Circ Cardiovasc Interv 10 : e005531, 2017
PubMed
14) Iida, O et al : 3-Year outcomes of the OLIVE Registry, a prospective multicenter study of patients with critical limb ischemia : A prospective, multi-center, three-year follow-up study on endovascular treatment for infra-inguinal vessel in patients with critical limb ischemia. JACC Cardiovasc Interv 8 : 1493-1502, 2015
PubMed
15) Conte, MS et al : Results of PREVENT III : a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43 : 742-751, 2006
 
16) Zeller, T et al : Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia : 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 64 : 1568-1576, 2014
 
17) Mustapha, JA et al : Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries : six-month results of the Lutonix BTK trial. J Invasive Cardiol 31 : 205-211, 2019
 
18) Hansen, KJ et al : Prevalence of renovascular disease in the elderly : a population-based study. J Vasc Surg 36 : 443-451, 2002
PubMed
19) Yamashita, T et al : Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 25 : 553-557, 2002
PubMed
20) Hackam, DG et al : Angiotensin inhibition in renovascular disease : a population-based cohort study. Am Heart J 156 : 549-555, 2008
PubMed
21) Bax, L et al : Stent placement in patients with atherosclerotic renal artery stenosis and impaired renalfunction : a randomized trial. Ann Intern Med 150 : 840-848, W150-151, 2009
 
22) Wheatley, K et al : Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361 : 1953-1962, 2009
PubMed
23) Cooper, CJ et al : Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 : 13-22, 2014
PubMed
P.314 掲載の参考文献
1) Jennette, JC et al : 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65 : 1-11, 2013
 
2) Gornik, HL et al : First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med 24 : 164-189, 2019
PubMed
3) Savard, S et al : Association between 2 angiographic subtypes of renal artery fibromuscular dysplasia and clinical characteristics. Circulation 126 : 3062-3069, 2012
PubMed
4) Trinquart, L et al : Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia : a systematic review and meta-analysis. Hypertension 56 : 525-532, 2010
PubMed
5) Insua, JA et al : Popliteal artery entrapment syndrome. Arch Surg 101 : 771-775, 1970
PubMed
6) Rich, NM et al : Popliteal vascular entrapment. Its increasing interest. Arch Surg 114 : 1377-1384, 1979
PubMed
7) 工藤敏文 : 第26章-A. 膝窩動脈捕捉症候群. 臨床脈管学, 日本脈管学会編, 日本医学出版, 東京, 298, 2017
 
8) 日本循環器学会 : 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2015_miyata_h.pdf (2020年10月閲覧)
 
P.318 掲載の参考文献
9) Mills, JL Sr : Buerger's disease in the 21st century : diagnosis, clinical features, and therapy. Semin Vasc Surg 16 : 179-189, 2003
 
10) Olin, JW et al : Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 18 : 18-24, 2006
 
11) Papa, MZ et al : A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 11 : 335-339, 1996
 
12) 日本循環器学会 : 血管炎症候群の診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf (2020年10月閲覧)
 
13) 日本循環器学会 : 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2015_miyata_h.pdf (2020年10月閲覧)
 
14) Pauling, JD et al : Raynaud's phenomenon -an update on diagnosis, classification and management. Clin Rheumatol 38 : 3317-3330, 2019
 
15) Kimura, Y et al : Outcomes of treatment strategies for isolated spontaneous dissection of the superior mesenteric artery : A systematic review. Ann Vasc Surg 47 : 284-290, 2018
PubMed
16) Sakamoto, I et al : Imaging appearances and management of isolated spontaneous dissection of the superior mesenteric artery. Eur J Radiol 64 : 103-110, 2007
PubMed
17) Yun, WS et al : Clinical and angiographic follow-up of spontaneous isolated superior mesenteric artery dissection. Eur J Vasc Endovasc Surg 37 : 572-577, 2009
PubMed
18) Bjorck, M et al : Editor's choice -Management of the diseases of mesenteric arteries and veins : clinical practice guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 53 : 460-510, 2017
 
19) Bjorck, M et al : Editor's choice -European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia. Eur J Vasc Endovasc Surg 59 : 173-218, 2020
 
20) Gerhard-Herman, MD et al : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2017 Mar 21 ; 135 (12) : e791-e792]. Circulation 135 : e726-e779, 2017
 
P.332 掲載の参考文献
1) Goyal, M et al : Endovascular thrombectomy after large-vessel ischaemic stroke : a meta-analysis of individual patient data from five randomised trials. Lancet 387 : 1723-1731, 2016
PubMed
2) Lyden, PD et al : A modified National Institutes of Health Stroke Scale for use in stroke clinical trials : preliminary reliability and validity. Stroke 32 : 1310-1317, 2001
PubMed
3) 日本脳卒中学会 : 静注血栓溶解 (rt-PA) 療法 適正治療指針 第三版. 脳卒中 41 : 205-246, 2019, https://www.jsts.gr.jp/img/rt-PA03.pdf (2020年1月閲覧)
 
4) Thomalla, G et al : MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 379 : 611-622, 2018
PubMed
5) Nogueira, RG et al : Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378 : 11-21, 2018
PubMed
6) Albers, GW et al : Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 378 : 708-718, 2018
PubMed
7) 日本脳卒中学会 脳卒中ガイドライン委員会編 : 脳卒中治療ガイドライン 2015〔追補2019対応〕. 協和企画, 東京, 2019
 
8) 日本脳卒中学会/日本脳神経外科学会/日本脳神経血管内治療学会 : 経皮経管的脳血栓回収用機器 適正使用指針 第4版. 脳卒中 42 : 281-313, 2020, https://www.jsts.gr.jp/img/noukessen_4.pdf (2020年1月閲覧)
 
9) Paciaroni, M et al : Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc 6 : e007034, 2017
PubMed
10) Powers, WJ et al : 2018 guidelines for the early management of patients with acute ischemic stroke : A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49 : e46-e110, 2018
PubMed
11) Hart, RG et al : Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol 13 : 429-438, 2014
PubMed
12) Sanna, T et al : Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 : 2478-2486, 2014
PubMed
13) 日本脳卒中学会 : 植込み型心電図記録計の適応となり得る潜因性脳梗塞患者の診断の手引き. 脳卒中 38 : 277-286, 2016, https://www.jsts.gr.jp/img/tebiki_noukousoku.pdf (2020年1月閲覧)
 
14) Ntaios, G et al : Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack : Updated systematic review and meta-analysis. Stroke 49 : 412-418, 2018
 
15) 日本脳卒中学会/日本循環器学会/日本心血管インターベンション治療学会 : 潜因性脳梗塞に対する経皮的卵円孔開存閉鎖術の手引き. 脳卒中 41 : 417-441, 2019, https://www.jsts.gr.jp/img/tebiki_seninsei_noukousoku.pdf (2020年1月閲覧)
 
16) Hart, RG et al : Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 379 : 987, 2018
PubMed
17) Diener, HC et al : Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380 : 1906-1917, 2019
PubMed
18) Wright, JT Jr et al : A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 : 2103-2116, 2015
PubMed
19) 日本高血圧学会高血圧治療ガイドライン作成委員会編 : 高血圧治療ガイドライン 2019, 日本高血圧学会, 2019
 
20) Kitagawa, K et al : Effect of standard vs intensive blood pressure control on the risk of recurrent stroke : A randomized clinical trial and meta-analysis. JAMA Neurol 76 : 1309-1318, 2019
PubMed
21) Sudlow, CL et al : Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2009 : CD001246, 2009
PubMed
22) Kamal, AK et al : Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011 : CD008076, 2011
PubMed
23) Toyoda, K et al : Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan : a multicentre, open-label, randomised controlled trial. Lancet Neurol 18 : 539-548, 2019
PubMed
24) Yasuda, S et al : Antithrombotic therapy for atrial fibrillation with stable coronary disease. Reply. N Engl J Med 381 : 2481, 2019
PubMed
25) Ziff, OJ et al : Statins and the risk of intracerebral haemorrhage in patients with stroke : systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 90 : 75-83, 2019
PubMed
26) Amarenco, P et al : A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 382 : 9, 2020
PubMed
P.343 掲載の参考文献
1) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf (2020年10月閲覧)
 
2) Heit, JA et al : The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41 : 3-14, 2016
PubMed
3) Ota, S et al : Incidence, characteristics and management of venous thromboembolism in Japan during 2011. Circ J 82 : 555-560, 2018
PubMed
4) Nakamura, M et al : Current venous thromboembolism management and outcomes in Japan. Circ J 78 : 708-717, 2014
PubMed
5) Yamashita, Y et al : Anticoagulation therapy for venous thromboembolism in the real world- From the COMMAND VTE Registry. Circ J 82 : 1262-1270, 2018
PubMed
6) Sakata, T et al : Prevalence of protein S deficiency in the Japanese general population : the Suita Study. J Thromb Haemost 2 : 1012-1013, 2004
PubMed
7) Prandoni, P et al : The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 : 1-7, 1996
 
8) Browse, NL et al : Deep vein thrombosis : pathology and diagnosis. Diseases of the Veins, 2nd ed, Browse, NL et al eds, Arnold, 249-291, 1999
 
9) Mudge, M et al : The long term sequelae of deep vein thrombosis. Br J Surg 65 : 692-694, 1978
 
10) 佐久間聖仁 : 急性肺血栓塞栓症の診断 : 今後の方向性. Ther Res 30 : 744-747, 2009
Medical*Online
11) Gibson, NS et al : Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 99 : 229-234, 2008
PubMed
12) Klok, FA et al : Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 168 : 2131-2136, 2008
PubMed
13) Hendriksen, JMT et al : Diagnostic prediction models for suspected pulmonary embolism : systematic review and independent external validation in primary care. BMJ 351 : h4438, 2015
 
14) Wells, PS et al : Does this patient have deep vein thrombosis? JAMA 295 : 199-207, 2006
PubMed
15) Konstantinides, SV et al : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 41 : 543-603, 2020
 
16) Aujesky, D et al : Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172 : 1041-1046, 2005
PubMed
17) Jimenez, D et al : Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170 : 1383-1389, 2010
PubMed
18) Righini, M et al : The Simplified Pulmonary Embolism Severity Index (PESI) : validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost 9 : 2115-2117, 2011
PubMed
19) Jaff, MR et al : Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension : a scientific statement from the American Heart Association. Circulation 123 : 1788-1830, 2011
PubMed
20) Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 21 : 1301-1336, 2000
 
21) Konstantinides, SV et al : 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism : The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) : Endorsed by the European Respiratory Society (ERS). Eur Heart J 35 : 3033-3069, 3069a-3069k, 2014
 
22) Raskob, GE et al : Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378 : 615-624, 2018
PubMed
23) Young, AM et al : Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : Results of a randomized trial (SELECT-D). J Clin Oncol 36 : 2017-2023, 2018
 
24) McBane, RD 2nd et al : Apixaban and dalteparin in active malignancy-associated venous thromboembolism : The ADAM VTE trial. J Thromb Haemost 18 : 411-421, 2020
 

第6章 心臓弁膜症

P.347 掲載の参考文献
1) Nkomo, VT et al : Burden of valvular heart diseases : a population-based study. Lancet 368 : 1005-1011, 2006
PubMed
2) Iung, B et al : A prospective survey of patients with valvular heart disease in Europe : the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24 : 1231-1243, 2003
PubMed
3) Andell, P et al : Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart 103 : 1696-1703, 2017
 
4) Benjamin, EJ et al : Heart disease and stroke statistics-2019 update. A report from the American Heart Association. Circulation 139 : e56-e528, 2019
PubMed
5) Basso, C et al : An echocardiographic survey of primary school children for bicuspid aortic valve. Am J Cardiol 93 : 661-663, 2004
PubMed
6) Iung, B et al : Degenerative calcific aortic stenosis : a natural history. Heart 98 : iv7-iv13, 2012
PubMed
7) Freed, LA et al : Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 341 : 1-7, 1999
PubMed
8) Bursi, F et al : Heart failure and death after myocardial infarction in the community : the emerging role of mitral regurgitation. Circulation 111 : 295-301, 2005
PubMed
9) Nath, J et al : Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 43 : 405-409, 2004
PubMed
P.354 掲載の参考文献
1) Linhart, JW : Aortic regurgitation. Clinical, hemodynamic, surgical, and angiographic correlations. Ann Thorac Surg 11 : 27-37, 1971
PubMed
2) Frank, MJ et al : The clinical evaluation of aortic regurgitation, with special reference to a neglected sign : the popliteal-brachial pressure gradient. Arch Intern Med 116 : 357-365, 1965
PubMed
3) Cha, SD et al : Diagnosis of tricuspid regurgitation. Current status. Arch Intern Med 143 : 1763-1768, 1983
PubMed
4) Greve, AM et al : Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis : the Simvastatin and Ezetimibe in Aortic Stenosis study. Circulation 125 : 346-353, 2012
PubMed
5) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
6) Nishimura, RA et al : 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017
 
7) Baumgartner, H et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease : The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 2739-2791, 2017
 
P.364 掲載の参考文献
1) Zoghbi, WA et al : Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation : A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30 : 303-371, 2017
 
2) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
3) Vahanian, A et al : Guidelines on the management of valvular heart disease (version 2012) : the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 42 : S1-S44, 2012
 
4) 日本心エコー図学会 : ASEガイドラインおよび基準値 弁逆流の非侵襲的評価に関する勧告. 2017, http://www.jse.gr.jp/contents/guideline/data/guideline%20regurgitation%20Japanese%202019-05-13.pdf (2020年1月閲覧)
 
5) Lancellotti, P et al : Recommendations for the echocardiographic assessment of native valvular regurgitation : an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 14 : 611-644, 2013
PubMed
6) Nishimura, RA et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 : e1159-e1195, 2017
 
7) Baumgartner, H et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease : The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 2739-2791, 2017
 
8) Grigioni, F et al : Ischemic mitral regurgitation long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103 : 1759-1764, 2001
PubMed
9) Goebel, B et al : Vena contracta area for severity grading in functional and degenerative mitral regurgitation : a transoesophageal 3D color Doppler analysis in 500 patients. Eur Heart J Cardiovasc Imaging 19 : 639-646, 2018
 
10) Grigioni, F et al : Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol 34 : 2078-2085, 1999
PubMed
11) McGee, EC et al : Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg 128 : 916-924, 2004
PubMed
12) Stone, GW et al : Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379 : 2307-2318, 2018
PubMed
13) Obadia, JF et al : Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379 : 2297-2306, 2018
 
P.369 掲載の参考文献
1) Nishimura, RA et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-e185, 2014
 
2) Shabsigh, M et al : Mitral valve stenosis after open repair surgery for non-rheumatic mitral valve regurgitation : a review. Front Cardiovasc Med 3 : 8, 2016
PubMed
3) Chandrashekhar, Y et al : Mitral stenosis. Lancet 374 : 1271-1283, 2009
PubMed
4) Essop, MR et al : Rheumatic and nonrheumatic valvular heart disease : epidemiology, management, and prevention in Africa. Circulation 112 : 3584-3591, 2005
PubMed
5) Osterberger, LE et al : Functional mitral stenosis in patients with massive mitral annular calcification. Circulation 64 : 472-476, 1981
PubMed
6) Abramowitz, Y et al : Mitral annulus calcification. J Am Coll Cardiol 66 : 1934-1941, 2015
PubMed
7) Kato, N et al : Hemodynamics and prognostic impact of concomitant mitral stenosis in patients undergoing surgical or transcatheter aortic valve replacement for aortic stenosis. Circulation 140 : 1251-1260, 2019
PubMed
8) Malanca, M et al : Radiotherapy-induced mitral stenosis : a three-dimensional perspective. J Am Soc Echocardiogr 23 : 108.e1-108.e2, 2010
 
9) Baumgartner, H et al : Echocardiographic assessment of valve stenosis : EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 22 : 1-23, 2009
PubMed
10) Sud, K et al : Degenerative Mitral Stenosis : Unmet Need for Percutaneous Interventions. Circulation 133 : 1594-1604, 2016
PubMed
11) 加藤奈穂子ほか : 高度MSの閾値は本当に1.5cm2なのか? やはり1.0cm2なのか? 心エコー 18 : 484-490, 2017
Medical*Online
12) Eleid, MF et al : Severe mitral annular calcification : multimodality imaging for therapeutic strategies and interventions. JACC Cardiovasc Imaging 9 : 1318-1337, 2016
PubMed
P.377 掲載の参考文献
1) Lindman, BR et al : Aortic valve Disease. Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine, 11 th ed, Zipes, DP et al eds, Elsevier, Philadelphia, 1389-1414, 2019
 
2) Nishimura, RA et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : 2440-2492, 2014
 
3) Baumgartner, H et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease : The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 2739-2786, 2017
 
4) Zoghbi, WA et al : Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation : A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30 : 303-371, 2017
 
5) Detaint, D et al : Quantitative echocardiographic determinants of clinical outcome in asymptomatic patients with aortic regurgitation : a prospective study. JACC Imaging 1 : 1-11, 2008
 
6) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
7) Mentias, A et al : Long-term outcomes in patients with aortic regurgitation and preserved left ventricular ejection fraction. J Am Coll Cardiol 68 : 2144-2153, 2016
PubMed
8) Yang, LT et al : Outcomes in chronic hemodynamically significant aortic regurgitation and limitations of current guidelines. J Am Coll Cardiol 73 : 1741-1752, 2019
PubMed
9) Amano, M et al : Pre- and postoperative predictors of long-term prognosis after aortic valve replacement for severe chronic aortic regurgitation. Circ J 80 : 2460-2467, 2016
PubMed
10) 日本循環器学会 : 血管炎症候群の診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/pdf/JCS2017_isobe_h.pdf (2020年10月閲覧)
 
P.385 掲載の参考文献
1) Sievers, HH et al : A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg 133 : 1226-1233, 2007
PubMed
2) Turina, J et al : Spontaneous course of aortic valve disease and indications for aortic valve replacement. Schweiz Med Wochenschr 118 : 508-516, 1988
PubMed
3) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
4) Hayashida, K et al : Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. Circ Cardiovasc Interv 6 : 284-291, 2013
PubMed
5) Hayashida, K et al : Impact of CT-guided valve sizing on post-procedural aortic regurgitation in transcatheter aortic valve implantation. EuroIntervention 8 : 546-555, 2012
PubMed
6) Jilaihawi, H et al : Aortic annular sizing for transcatheter aortic valve replacement using cross-sectional 3-dimensional transesophageal echocardiography. J Am Coll Cardiol 61 : 908-916, 2013
PubMed
7) Hayashida, K et al : Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. Circ Cardiovasc Interv 6 : 284-291, 2013
PubMed
8) Yoon, SH et al : Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol 69 : 2579-2589, 2017
PubMed
9) Yoon, SH et al : Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol 68 : 1195-1205, 2016
PubMed
10) Makkar, RR et al : Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373 : 2015-2024, 2015
PubMed
11) Chakravarty, T et al : Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves : an observational study. Lancet 389 : 2383-2392, 2017
PubMed
12) Kakefuda, Y et al : Impact of subclinical vascular complications detected by systematic postprocedural multidetector computed tomography after transcatheter aortic valve implantation using balloon-expandable Edwards SAPIEN XT heart valve. Am J Cardiol 119 : 1100-1105, 2017
PubMed
13) Yanagisawa, R et al : Early and late leaflet thrombosis after transcatheter aortic valve replacement. Circ Cardiovasc Interv 12 : e007349, 2019
PubMed
14) Nishimura, RA et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017
 
15) Baumgartner, H et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease : The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 2739-2791, 2017
 
16) Leon, MB et al : Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 : 1609-1620, 2016
 
17) Thourani, VH et al : Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients : a propensity score analysis. Lancet 387 : 2218-2225, 2016
PubMed
18) Reardon, MJ et al : Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376 : 1321-1331, 2017
 
19) Popma, JJ et al : Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380 : 1706-1715, 2019
PubMed
20) Mack, MJ et al : Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380 : 1695-1705, 2019
PubMed
21) Shimizu, H et al : Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 67 : 377-411, 2019
PubMed
22) Handa, N et al : Learning curve for transcatheter aortic valve implantation under a controlled introduction system -Initial analysis of a Japanese nationwide registry. Circ J 82 : 1951-1958, 2018
 
23) Yamamoto, M et al : Transcatheter aortic valve replacement outcomes in Japan : Optimized CathEter vAlvular iNtervention (OCEAN) Japanese multicenter registry. Cardiovasc Revasc Med 20 : 843-851, 2019
PubMed
24) Shimura, T et al : Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation 135 : 2013-2024, 2017
PubMed
25) Hayashida, K et al : Impact of post-procedural aortic regurgitation on mortality after transcatheter aortic valve implantation. JACC Cardiovasc Interv 5 : 1247-1256, 2012
PubMed
26) Yoshijima, N et al : Update on the clinical impact of mild aortic regurgitation after transcatheter aortic valve implantation : Insights from the Japanese multicenter OCEAN-TAVI registry. Catheter Cardiovasc Interv 95 : 35-44, 2020
PubMed
27) Hayashida, K et al : Transfemoral aortic valve implantation : new criteria to predict vascular complications. JACC Cardiovasc Interv 4 : 851-858, 2011
PubMed
28) Sathananthan, J et al : Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement. Catheter Cardiovasc Interv, 2020 (Epub ahead of print)
 
29) Capodanno, D et al : Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves : a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 3382-3390, 2017
 
P.395 掲載の参考文献
1) Arsalan, M et al : Tricuspid regurgitation diagnosis and treatment. Eur Heart J 38 : 634-638, 2017
PubMed
2) Nath, J et al : Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 43 : 405-409, 2004
PubMed
3) Zoghbi, WA et al : Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation : A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30 : 303-371, 2017
 
4) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
5) Nishimura, RA et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-643, 2014
 
6) Baumgartner, H et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 2739-2791, 2017
 
7) Benedetto, U et al : Prophylactic tricuspid annuloplasty in patients with dilated tricuspid annulus undergoing mitral valve surgery. J Thorac Cardiovasc Surg 143 : 632-638, 2012
PubMed
8) Axtell, AL et al : Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol 74 : 715-725, 2019
 
9) Shimizu, H et al : Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 67 : 377-411, 2019
PubMed
10) Asmarats, L et al : Transcatheter tricuspid valve interventions : landscape, challenges, and future directions. J Am Coll Cardiol 71 : 2935-2956, 2018
PubMed
11) Warnes, CA et al : ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 118 : e714-e833, 2008
 
12) Stout, KK et al : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2019 Apr 2 ; 139 (14) : e833-e834]. Circulation 139 : e698-e800, 2019
 
13) Chen, CR et al : Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults. N Engl J Med 335 : 21-25, 1996
PubMed
14) Bouzas, B et al : Pulmonary regurgitation : not a benign lesion. Eur Heart J 26 : 433-439, 2005
 
15) Puchalski, MD et al : Pulmonary regurgitation : determining severity by echocardiography and magnetic resonance imaging. Congenit Heart Dis 3 : 168-175, 2008
PubMed
16) Mercer-Rosa, L et al : Quantifying pulmonary regurgitation and right ventricular function in surgically repaired tetralogy of Fallot : a comparative analysis of echocardiography and magnetic resonance imaging. Circ Cardiovasc Imaging 5 : 637-643, 2012
PubMed
P.400 掲載の参考文献
1) Pibarot, P et al : Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol 36 : 1131-1141, 2000
PubMed
2) Puskas, J et al : Reduced anticoagulation after mechanical aortic valve replacement : interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 147 : 1202-1210 ; discussion 1210-1211, 2014
 
3) Wang, M et al : Bioprosthetic aortic valve durability : A meta-regression of published studies. Ann Thorac Surg 10 : 1080-1087, 2017
PubMed
4) Flameng, W et al : A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg 149 : 340-345, 2015
 
5) Kocher, AA et al : One-year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial : a prospective multicenter study of rapid-deployment aortic valve replacement with the EDWARDS INTUITY Valve System. J Thorac Cardiovasc Surg 145 : 110-115 ; discussion 115-116, 2013
 
6) Barnhart, GR et al : TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) US clinical trial : Performance of a rapid deployment aortic valve. J Thorac Cardiovasc Surg 153 : 241-251.e2, 2017
 
7) Borger, MA et al : Haemodynamic benefits of rapid deployment aortic valve replacement via a minimally invasive approach : 1-year results of a prospective multicentre randomized controlled trial. Eur J Cardiothorac Surg 50 : 713-720, 2016
 
8) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
9) Schnittman, SR et al : Bioprosthetic aortic valve replacement : Revisiting prosthesis choice in patients younger than 50 years old. J Thorac Cardiovasc Surg 155 : 539-547.e9, 2018
 
10) Tuzcu, EM et al : Transcatheter aortic valve replacement of failed surgically implanted bioprostheses : The STS/ACC registry. J Am Coll Cardiol 72 : 370-382, 2018
PubMed
11) Pibarot, P et al : Impact of pre-existing prosthesis-patient mismatch on survival following aortic valve-in-valve procedures. JACC Cardiovasc Interv 11 : 133-141, 2018
PubMed
P.409 掲載の参考文献
1) Ahtela, E et al : Trends in occurrence and 30-day mortality of infective endocarditis in adults : population-based registry study in Finland. BMJ Open 9 : e026811, 2019
PubMed
2) Habib, G et al : Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry : a prospective cohort study. Eur Heart J 40 : 3222-3232, 2019
PubMed
3) Hasbun, R et al : Complicated left-sided native valve endocarditis in adults : risk classification for mortality. JAMA 289 : 1933-1940, 2003
PubMed
4) Nadji, G et al : Heart failure in left-sided native valve infective endocarditis : characteristics, prognosis, and results of surgical treatment. Eur J Heart Fail 11 : 668-675, 2009
PubMed
5) Olmos, C et al : Comparison of clinical features of left-sided infective endocarditis involving previously normal versus previously abnormal valves. Am J Cardiol 114 : 278-283, 2014
PubMed
6) Roux, V et al : Coronary events complicating infective endocarditis. Heart 103 : 1906-1910, 2017
PubMed
7) Anguera, I et al : Periannular complications in infective endocarditis involving prosthetic aortic valves. Am J Cardiol 98 : 1261-1268, 2006
PubMed
8) Di Salvo, G et al : Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 37 : 1069-1076, 2001
PubMed
9) Okazaki, S et al : Acute ischemic brain lesions in infective endocarditis : incidence, related factors, and postoperative outcome. Cerebrovasc Dis 35 : 155-162, 2013
PubMed
10) Park, LP et al : Validated risk score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc 5 : e003016, 2016
PubMed
11) Yoshioka, D et al : Impact of early surgical treatment on postoperative neurologic outcome for active infective endocarditis complicated by cerebral infarction. Ann Thorac Surg 94 : 489-495 ; discussion 496, 2012
 
12) Mohananey, D et al : Association of vegetation size with embolic risk in patients with infective endocarditis : a systematic review and meta-analysis. JAMA Intern Med 178 : 502-510, 2018
PubMed
13) Suzuki, K et al : Results of surgical management of infective endocarditis associated with Staphylococcus aureus. Eur J Cardiothorac Surg 56 : 30-37, 2019
PubMed
14) Dickerman, SA et al : The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis : an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 154 : 1086-1094, 2007
PubMed
15) Olmos, C et al : The evolving nature of infective endocarditis in Spain : a population-based study (2003 to 2014). J Am Coll Cardiol 70 : 2795-2804, 2017
 
16) Pant, S et al : Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 65 : 2070-2076, 2015
PubMed
17) van den Brink, FS et al : Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update : a nationwide study in the Netherlands. Eur Heart J Qual Care Clin Outcomes 3 : 141-147, 2017
 
18) Dayer, MJ et al : Incidence of infective endocarditis in England, 2000-13 : a secular trend, interrupted time-series analysis. Lancet 385 : 1219-1228, 2015
PubMed
19) Garcia-Cabrera, E et al : Neurological complications of infective endocarditis : risk factors, outcome, and impact of cardiac surgery : a multicenter observational study. Circulation 127 : 2272-2284, 2013
PubMed
20) Ostergaard, L et al : Incidence of infective endocarditis among patients considered at high risk. Eur Heart J 39 : 623-629, 2018
PubMed
21) Ostergaard, L et al : Incidence of infective endocarditis in patients considered at moderate risk. Eur Heart J 40 : 1355-1361, 2019
PubMed
22) Movahed, MR et al : Increased prevalence of infectious endocarditis in patients with type II diabetes mellitus. J Diabetes Complications 21 : 403-406, 2007
PubMed
23) Critchley, JA et al : Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 41 : 2127-2135, 2018
PubMed
24) Ostergaard, L et al : Duration and complications of diabetes mellitus and the associated risk of infective endocarditis. Int J Cardiol 278 : 280-284, 2019
PubMed
25) Yoshioka, D et al : Diabetes mellitus adversely affects mortality and recurrence after valve surgery for infective endocarditis. J Thorac Cardiovasc Surg 155 : 1021-1029.e5, 2018
 
26) Abbott, KC et al : Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 91 : 203-209, 2002
PubMed
27) Chaudry, MS et al : Risk of infective endocarditis in patients with end stage renal disease. Clin J Am Soc Nephrol 12 : 1814-1822, 2017
PubMed
28) Deo, SV et al : Admissions for infective endocarditis in intravenous drug users. J Am Coll Cardiol 71 : 1596-1597, 2018
PubMed
29) Ostergaard, L et al : Prevalence of infective endocarditis in patients with positive blood cultures : a Danish nationwide study. Eur Heart J 40 : 3237-3244, 2019
PubMed
30) Nakatani, S et al : Recent picture of infective endocarditis in Japan -lessons from Cardiac Disease Registration (CADRE-IE). Circ J 77 : 1558-1564, 2013
PubMed
31) Li, JS et al : Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30 : 633-638, 2000
 
32) Habib, G et al : 2015 ESC Guidelines for the management of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015
 
33) 日本循環器学会 : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/07/JCS2017_nakatani_h.pdf (2020年10月閲覧)
 
34) Murdoch, DR et al : Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century : the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169 : 463-473, 2009
PubMed
35) Chu, VH et al : Association between surgical indications, operative risk, and clinical outcome in infective endocarditis : a prospective study from the International Collaboration on Endocarditis. Circulation 131 : 131-140, 2015
PubMed
36) Yokoyama, J et al : Surgery-first treatment improves clinical results in infective endocarditis complicated with disseminated intravascular coagulation. Eur J Cardiothorac Surg 56 : 785-792, 2019
PubMed
37) Matsuura, R et al : Effect of the initial strategy for active endocarditis complicated with acute heart failure. Circ J 82 : 2896-2904, 2018
PubMed
38) Byrne, JG et al : Surgical management of endocarditis : the society of thoracic surgeons clinical practice guideline. Ann Thorac Surg 91 : 2012-2019, 2011
 
39) Eishi, K et al : Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg 110 : 1745-1755, 1995
PubMed
40) Thuny, F et al : Risk of embolism and death in infective endocarditis : prognostic value of echocardiography : a prospective multicenter study. Circulation 112 : 69-75, 2005
 
41) Ghoreishi, M et al : Early operation in patients with mitral valve infective endocarditis and acute stroke is safe. Ann Thorac Surg 105 : 69-75, 2018
PubMed
42) Okita, Y et al : Optimal timing of surgery for active infective endocarditis with cerebral complications : a Japanese multicentre study. Eur J Cardiothorac Surg 50 : 374-382, 2016
PubMed
43) Snygg-Martin, U et al : Cerebrovascular complications in patients with left-sided infective endocarditis are common : a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis 47 : 23-30, 2008
 
44) Iung, B et al : Determinants of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging : a prospective study. Stroke 44 : 3056-3062, 2013
PubMed
45) Samura, T et al : Emergency valve surgery improves clinical results in patients with infective endocarditis complicated with acute cerebral infarction : analysis using propensity score matching. Eur J Cardiothorac Surg 56 : 942-949, 2019
PubMed
46) Baddour, LM et al : Infective endocarditis in adults : diagnosis, antimicrobial therapy, and management of complications : a scientific statement for healthcare professionals from the American Heart Association. Circulation 132 : 1435-1486, 2015
PubMed
47) Yoshioka, D et al : Valve surgery in active endocarditis patients complicated by intracranial haemorrhage : the influence of the timing of surgery on neurological outcomes. Eur J Cardiothorac Surg 45 : 1082-1088, 2014
PubMed
48) Ohira, S et al : Prediction of early postoperative cerebral hemorrhage in infective endocarditis patients using magnetic resonance imaging. Gen Thorac Cardiovasc Surg 62 : 608-613, 2014
PubMed
49) Okazaki, S et al : Cerebral microbleeds predict impending intracranial hemorrhage in infective endocarditis. Cerebrovasc Dis 32 : 483-488, 2011
PubMed
50) Yoshioka, D et al : Anemia is a risk factor of new intraoperative hemorrhagic stroke during valve surgery for endocarditis. Ann Thorac Surg 100 : 16-23, 2015
PubMed
51) Yoshioka, D et al : Recent surgical results for active endocarditis complicated with perivalvular abscess. Circ J 81 : 1721-1729, 2017
PubMed
52) Lee, HA et al : Nationwide cohort study of mitral valve repair versus replacement for infective endocarditis. J Thorac Cardiovasc Surg 156 : 1473-1483.e2, 2018
 
53) Savage, EB et al : Outcomes and prosthesis choice for active aortic valve infective endocarditis : analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 98 : 806-814, 2014
 
54) Tao, E et al : The prognosis of infective endocarditis treated with biological valves versus mechanical valves : A meta-analysis. PLoS One 12 : e0174519, 2017
 
55) Toyoda, N et al : Bioprosthetic versus mechanical valve replacement for infective endocarditis : focus on recurrence rates. Ann Thorac Surg 106 : 99-106, 2018
PubMed
56) Kyto, V et al : Mechanical versus biological valve prosthesis for surgical aortic valve replacement in patients with infective endocarditis. Interact Cardiovasc Thorac Surg 29 : 386-392, 2019
PubMed

第7章 心筋疾患・心膜疾患

P.419 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf (2020年10月閲覧)
 
2) Herman, DS et al : Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366 : 619-628, 2012
PubMed
3) 森田啓行 : 遺伝子から心筋症をみる. 日内会誌 103 : 285-292, 2014
 
4) 森田啓行 : 心不全の原因としてのタイチン遺伝子変異. 循環器内科 86 : 114-119, 2019
 
5) Morita, H et al : Genetic causes of human heart failure. J Clin Invest 115 : 518-526, 2005
PubMed
6) 後藤義崇ほか : MRIによる心筋疾患の診断. 日内会誌 105 : 2041-2047, 2016
 
7) Marcus, FI et al : Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia : proposed modification of the task force criteria. Circulation 121 : 1533-1541, 2010
PubMed
8) 森田啓行 : 筋ジストロフィー心筋症. 医学のあゆみ 268 : 705-710, 2019
Medical*Online
9) Tobita, T et al : Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 8 : 1998, 2018
PubMed
10) Ko, T et al : Quantification of DNA damage in heart tissue as a novel prediction tool for therapeutic prognosis of patients with dilated cardiomyopathy. JACC Basic Transl Sci 4 : 670-680, 2019
PubMed
11) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
P.428 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf (2020年10月閲覧)
 
2) Elliott, PM et al : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy : the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 : 2733-2779, 2014
 
3) Maron, BJ : Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 379 : 655-668, 2018
PubMed
4) Braunwald, E ed : Heart disease : A Textbook of Cardiovascular Medicine, 5th ed, WB Saunders, Philadelphia, 1420, 1997
 
5) Rowin, EJ et al : Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 10 : 1374-1386, 2017
PubMed
6) Maron, BJ et al : Hypertrophic cardiomyopathy. Lancet 381 : 242-255, 2013
PubMed
7) ファブリー病診断治療ハンドブック編集委員会編 : ファブリー病診断治療ハンドブック, 改訂第3版, イーエヌメディックス, 東京, 2018
 
8) Gersh, BJ et al : 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58 : e212-e260, 2011
 
P.434 掲載の参考文献
1) Marcus, FI et al : Right ventricular dysplasia : a report of 24 adult cases. Circulation 65 : 384-398, 1982
PubMed
2) Thiene, G et al : Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318 : 129-133, 1988
PubMed
3) Corrado, D et al : Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia : a multicenter study. J Am Coll Cardiol 30 : 1512-1520, 1997
PubMed
4) Bhonsale, A et al : Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 36 : 847-855, 2015
PubMed
5) Protonotarios, A et al : Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy. Europace 18 : 610-616, 2016
PubMed
6) Horimoto, M et al : Evolution of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Cardiology 93 : 197-200, 2000
PubMed
7) Sen-Chowdhry, S et al : Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited : comparison with task force criteria and genotype. J Am Coll Cardiol 48 : 2132-2140, 2006
PubMed
8) Rampazzo, A et al : The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet 3 : 959-962, 1994
PubMed
9) McKoy, G1 et al : Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355 : 2119-2124, 2000
 
10) McKenna, WJ et al : Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 71 : 215-218, 1994
 
11) Marcus, FI et al : Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia : proposed modification of the task force criteria. Circulation 121 : 1533-1541, 2010
PubMed
12) James, CA et al : Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 62 : 1290-1297, 2013
PubMed
P.439 掲載の参考文献
1) Pereira, NL et al : Spectrum of restrictive and infiltrative cardiomyopathies : part 1 of a 2-part series. J Am Coll Cardiol 71 : 1130-1148, 2018
 
2) Kubo, T et al : Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49 : 2419-2426, 2007
PubMed
3) Ammash, NM et al : Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101 : 2490-2496, 2000
PubMed
4) Webber, SA et al : Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype : a report from the Pediatric Cardiomyopathy Registry. Circulation 126 : 1237-1244, 2012
PubMed
5) Gallego-Delgado, M et al : Idiopathic restrictive cardiomyopathy is primarily a genetic disease. J Am Coll Cardiol 67 : 3021-3023, 2016
PubMed
6) Hayashi, T et al : Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy. J Hum Genet 63 : 989-996, 2018
PubMed
7) Gomes, AV et al : Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem 280 : 30909-30915, 2005
PubMed
8) Geske, JB et al : Differentiation of constriction and restriction : complex cardiovascular hemodynamics. J Am Coll Cardiol 68 : 2329-2347, 2016
PubMed
9) Zaleta-Rivera, K et al : Allele-specific silencing ameliorates restrictive cardiomyopathy attributable to a human myosin regulatory light chain mutation. Circulation 140 : 765-778, 2019
PubMed
10) Rivenes, SM et al : Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 102 : 876-882, 2000
PubMed
11) Matsumori, A et al : Epidemiologic and clinical characteristics of cardiomyopathies in Japan : results from nationwide surveys. Circ J 66 : 323-336, 2002
PubMed
P.443 掲載の参考文献
1) Kamiya, CA et al : Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy-. Circ J 75 : 1975-1981, 2011
PubMed
2) Kamiya, CA et al : Peripartum cardiomyopathy from a genetic perspective. Circ J 80 : 1684-1688, 2016
PubMed
3) Bello, N et al : The relationship between pre-eclampsia and peripartum cardiomyopathy : a systematic review and meta-analysis. J Am Coll Cardiol 62 : 1715-1723, 2013
PubMed
4) Hilfiker-Kleiner, D et al : A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 : 589-600, 2007
PubMed
5) Patten, IS et al : Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485 : 333-338, 2012
PubMed
6) Ware, JS et al : Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374 : 233-241, 2016
PubMed
7) 厚生労働科学研究 (難治性疾患政策研究事業) 「周産期 (産褥性) 心筋症の, 早期診断検査確立研究の継続と診断ガイドライン作成」班・「特発性心筋症に関する調査研究」班編 : 周産期心筋症診療の手引き, 中外医学社, 東京, 2019
 
8) Sliwa K, et al : Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy : a proof-of-concept pilot study. Circulation 121 : 1465-1473, 2010
PubMed
9) Hilfiker-Kleiner, D et al : Bromocriptine for the treatment of peripartum cardiomyopathy : a multicentre randomized study. Euro Heart J 38 : 2671-2679, 2017
 
10) Sliwa, K et al : Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy : practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail 20 : 951-962, 2018
 
11) Elkayam, U : Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 64 : 1629-1636, 2014
PubMed
P.452 掲載の参考文献
1) 日本循環器学会 : 循環器病ガイドラインシリーズ 2016年版 心臓サルコイドーシスの診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_terasaki_h.pdf (2020年10月閲覧)
 
2) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシス診療の手引き 2018. http://jssog.com/www/top/kenkai20118.html (2020年1月閲覧)
 
3) Yamano, T et al : Cardiac sarcoidosis : What can we know from echocardiography? J Echocardiogr 5 : 1-10, 2007
 
4) Watanabe, E et al : Late gadolinium enhancement in cardiac sarcoidosis : characteristic magnetic resonance findings and relationship with left ventricular function. J Thorac Imaging, 28 : 60-66, 2013
PubMed
5) Kumita, S et al : Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update : Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Cardiol 5 : 141-159, 2019
 
6) Youssef, G et al : The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis : a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53 : 241-248, 2012
 
7) Osborne, MT et al : Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 21 : 166-174, 2014
PubMed
8) 日本サルコイドーシス/肉芽腫性疾患学会ほか : サルコイドーシス治療に関する見解-2003. 日サ会誌 23 : 105-114, 2003
 
9) Birnie DH, et al : Cardiac sarcoidosis. J Am Coll Cardiol 68 : 411-421, 2016
PubMed
10) Birnie DH, et al : HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 : 1305-1323, 2014
PubMed
P.460 掲載の参考文献
1) Falk, RH : Diagnosis and management of the cardiac amyloidoses. Circulation 112 : 2047-2060, 2005
PubMed
2) Falk, RH et al : The systemic amyloidosis. N Engl J Med 337 : 898-909, 1997
PubMed
3) Gillmore, JD et al : Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133 : 2404-2412, 2016
PubMed
4) Falk, RH : Cardiac amyloidosis : a treatable disease, often overlooked. Circulation 124 : 1079-1085, 2011
PubMed
5) Klein, AL et al : Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiology study. Circulation 83 : 808-816, 1991
 
6) Koyama, J et al : Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 89 : 1067-1071, 2002
PubMed
7) Buss, SJ et al : Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis : incremental value compared with clinical biochemical markers. J Am Coll Cardiol 60 : 1067-1076, 2012
PubMed
8) Liu, D et al : Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 6 : 1066-1072, 2013
PubMed
9) Muchtar, E et al : Immunoglobulin light-chain amyloidosis : from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol 135 : 172-190, 2016
PubMed
10) Kumar, S et al : Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 : 989-995, 2012
PubMed
11) Maurer, MS et al : Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Eng J Med 379 : 1007-1016, 2018
 
P.468 掲載の参考文献
1) Strubelt, O et al : Experimental treatment of the acute cardiovascular toxicity of caffeine. J Toxicol Clin Toxicol 37 : 29-33, 1999
PubMed
2) Vukcevic, NP et al : Severe acute caffeine poisoning due to intradermal injections : mesotherapy hazard. Vojnosanit Pregl 69 : 707-713, 2012
PubMed
3) Fabrizio, C et al : Electrocardiogram abnormalities of caffeine overdose. Circ Arrhythm Electrophysiol 9 : e003088, 2016
PubMed
4) Wilson, RE et al : A case of caffeine-induced coronary artery vasospasm of a 17-year-old male. Cardiovasc Toxicol 12 : 175-179, 2012
PubMed
5) Enriquez, A et al : Arrhythmogenic effects of energy drinks. J Cardiovasc Electrophysiol 28 : 711-717, 2017
PubMed
6) Moller, JE et al : Factors associated with progression of carcinoid heart disease. N Engl J Med 348 : 1005-1015, 2003
PubMed
7) Vasudev, R et al : Selective serotonin-norepinephrine reuptake inhibitors-induced takotsubo cardiomyopathy. N Am J Med Sci 8 : 312-315, 2016
PubMed
8) Boyer, EW et al : The serotonin syndrome. N Engl J Med 352 : 1112-1120, 2005
PubMed
9) Mladenka, P et al : Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev 38 : 1332-1403, 2018
PubMed
10) Costa, VM et al : Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr Med Chem 18 : 2272-2314, 2011
 
11) Won, S et al : Methamphetamine-associated cardiomyopathy. Clin Cardiol 36 : 737-742, 2013
PubMed
12) Sylvester, AL et al : Acute myocardial infarction in a teenager due to Adderall XR. Pediatr Cardiol 33 : 155-157, 2012
 
13) Marks, DH : Cardiomyopathy due to ingestion of Adderall. Am J Ther 15 : 287-289, 2008
PubMed
14) Alsidawi, S et al : Adderall induced inverted-takotsubo cardiomyopathy. Catheter Cardiovasc Interv 78 : 910-913, 2011
PubMed
15) Smith, HJ et al : Cardiomyopathy associated with amphetamine administration. Am Heart J 91 : 792-797, 1976
PubMed
16) Movahed, MR et al : Reverse or inverted left ventricular apical ballooning syndrome (reverse takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use. Echocardiography 25 : 429-432, 2008
 
17) Guzzo-Merello, G et al : Natural history and prognostic factors in alcoholic cardiomyopathy. JACC Heart Fail 3 : 78-86, 2015
PubMed
18) Fauchier, L et al : Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 21 : 306-314, 2000
PubMed
19) Urbano-Marquez, A et al : The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 274 : 149-154, 1995
PubMed
20) Tonelo, D et al : Holiday heart syndrome revisited after 34 years. Arq Bras Cardiol 101 : 183-189, 2013
PubMed
P.480 掲載の参考文献
1) 日本循環器学会 : 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版) https://www.j-circ.or.jp/cms/wpcontent/uploads/2020/02/JCS2009_izumi_h.pdf (2020年10月閲覧)
 
2) Caforio, ALP et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2013
 
3) Global Burden of Disease Study 2013 Collaborators : Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013 : a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 : 743-800, 2015
PubMed
4) Liu, PP et al : Advances in the understanding of myocarditis. Circulation 104 : 1076-1082, 2001
PubMed
5) Kindermann, I et al : Update on myocarditis. J Am Coll Cardiol 59 : 779-792, 2012
PubMed
6) Tschope, C et al : Mechanical unloading by fulminant myocarditis : LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA concepts. J Cardiovasc Transl Res 12 : 116-123, 2019
PubMed
7) Atkinson, TM et al : A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention : an interventional perspective. JACC Cardiovasc Interv 9 : 871-883, 2016
PubMed
8) Veronese, G et al : Fulminant myocarditis : Characteristics, treatment, and outcomes. Anatol J Cardiol 19 : 279-286, 2018
 
9) Ammirati, E et al : Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation 136 : 529-545, 2017
PubMed
10) Brambatti, M et al : Eosinophilic myocarditis characteristics, treatment, and outcomes. J Am Coll Cardiol 70 : 2363-2375, 2017
PubMed
11) Xu, J et al : Giant cell myocarditis : A brief review. Arch Pathol Lab Med 140 : 1429-1434, 2016
PubMed
12) Kuhl, U et al : Treatment of chronic myocarditis with corticosteroids. Eur Heart J 16 : 168-172, 1995
PubMed
P.489 掲載の参考文献
1) Wong, CX et al : Epicardial fat and atrial fibrillation : current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J 38 : 1294-1302, 2017
PubMed
2) Imazio, M et al : Myopericarditis versus viral or idiopathic acute pericarditis. Heart 94 : 498-501, 2008
PubMed
3) LeWinter, MM : Clinical practice. Acute pericarditis. N Engl J Med 371 : 2410-2416, 2014
PubMed
4) Imazio, M et al : Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis : implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 123 : 1092-1097, 2011
PubMed
5) Imazio, M et al : Evaluation and treatment of pericarditis : a systematic review. JAMA 314 : 1498-1506, 2015
PubMed
6) Oh, JK et al : Diagnostic role of Doppler echocardiography in constrictive pericarditis. J Am Coll Cardiol 23 : 154-162, 1994
PubMed
7) Leya, FS et al : The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45 : 1900-1902, 2005
PubMed
8) George, TJ et al : Contemporary etiologies, risk factors, and outcomes after pericardiectomy. Ann Thorac Surg 94 : 445-451, 2012
PubMed
9) Klein, AL et al : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease : endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 26 : 965-1012.e15, 2013
 
10) Sun, JS et al : CT findings in patients with pericardial effusion : differentiation of malignant and benign disease. AJR Am J Roentgenol 194 : W489-W494, 2010
PubMed
11) Adler, Y et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015
 
P.496 掲載の参考文献
1) 天野 純ほか : [1] -2. 心臓腫瘍の疫学・頻度. 心臓腫瘍学, 天野純編, 南山堂, 東京, 8-18, 2011
 
2) Burke, A et al : The 2015 WHO classification of tumors of the heart and pericardium. J Thorac Oncol 11 : 441-452, 2016
PubMed
3) Travis, WD et al eds : WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed, International Agency for Research on Cancer, Lyon, 2015
 
4) Burke, A et al : Tumors of the Heart and Great Vessels. Atlas of Tumor Pathology, 3rd Series, Fascicle 16, Rosai, J et al eds, Armed Forces Institute of Pathology, Washington DC, 1996
 
5) Amano, J et al : Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. Gen Thorac Cardiovasc Surg 61 : 435-447, 2013
PubMed
6) Bruce, CJ : Cardiac tumours : diagnosis and management. Heart 97 : 151-160, 2011
PubMed
7) Araoz, PA et al : CT and MR imaging of benign primary cardiac neoplasms with echocardiographic correlation. Radiographics 20 : 1303-1319, 2000
 
8) Grinda, JM et al : Cardiac valve papillary fibroelastoma : surgical excision for revealed or potential embolization. J Thorac Cardiovasc Surg 117 : 106-110, 1999
PubMed

第8章 肺高血圧症

P.501 掲載の参考文献
1) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 
2) Simonneau, G et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 : D34-D41, 2013
PubMed
3) Galie, N et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 : 67-119, 2016
 
4) 日本肺高血圧・肺循環学会 : 結合組織病に伴う肺動脈性肺高血圧症 診療ガイドライン. 2019, http://jpcphs.org/pdf/guideline/ketugou_guideline.pdf (2020年1月閲覧)
 
5) 渡邉裕司企画 : 肺高血圧症 Cutting Edge. 循環器ジャーナル 66, 2018
 
6) Sahay, S : Evaluation and classification of pulmonary arterial hypertension. J Thorac Dis 11 : S1789-S1799, 2019
PubMed
P.509 掲載の参考文献
1) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 
2) Simonneau, G et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 : 1801913, 2019.
PubMed
3) Simonneau, G et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 : D34-D41, 2013
PubMed
4) 厚生労働省 : 平成30年度衛生行政報告例 特定医療費 (指定難病) 受給者証所持者数, 年齢階級・対象疾患別. https://www.e-stat.go.jp/stat-search/file-download?statInfId=000031873765&fileKind=1 (2020年1月閲覧)
 
5) Galie, N et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 : 67-119, 2016
 
6) Sawada, H et al : Detection of pediatric pulmonary arterial hypertension by school electrocardiography mass screening. Am J Respir Crit Care Med 199 : 1397-1406, 2019
PubMed
7) Ogawa, A : Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. J Cardiol 72 : 255-260, 2018
PubMed
8) Kim, NH et al : Chronic thromboembolic pulmonary hypertension. Eur Respir J 53 : 1801915, 2019
PubMed
9) Baggen, VJM et al : Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension : a systematic review and meta-analysis. Eur Radiol 26 : 3771-3780, 2016
 
10) Galie, N et al : Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 53 : 1801889, 2019
PubMed
11) Ogawa, A et al : Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am J Cardiol 119 : 1479-1484, 2017
PubMed
12) Galie, N et al : Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373 : 834-844, 2015
PubMed
13) Tamura, Y et al : Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J 82 : 275-282, 2017
PubMed
14) Sitbon, O et al : Upfront triple combination therapy in pulmonary arterial hypertension : a pilot study. Eur Respir J 43 : 1691-1697, 2014
PubMed
15) Akagi, S et al : Marked hemodynamic improvements by highdose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J 74 : 2200-2205, 2010
 
16) Tokunaga, N et al : Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol 68 : 542-547, 2016
PubMed
17) Ogawa, A et al : Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118 : 414-419, 2014
 
18) Rich, S et al : The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 : 76-81, 1992
PubMed
19) Krowka, MJ et al : Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6 : 443-450, 2000
PubMed
20) Farber, HW et al : Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 148 : 1043-1054, 2015
PubMed
P.515 掲載の参考文献
1) Vachiery, JL et al : Pulmonary hypertension due to left heart disease. Eur Respir J 53 : 1801897, 2019
PubMed
2) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 
3) Opitz, CF et al : Pre-capillary, combined, and post-capillary pulmonary hypertension : a pathophysiological continuum. J Am Coll Cardiol 68 : 368-378, 2016
PubMed
4) Hsu, S et al : Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation 137 : 2360-2370, 2018
PubMed
5) Kim, NH et al : Chronic thromboembolic pulmonary hypertension. Eur Respir J 53 : 1801915, 2019
PubMed
6) Herve, P et al : Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J 46 : 728-737, 2015
PubMed
7) Tatebe, S et al : Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. Circ J 76 : 1235-1244, 2012
PubMed
8) Caravita, S et al : Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease : a meta-analysis. Eur Respir J 51 : 1702427, 2018
PubMed
P.522 掲載の参考文献
1) Shirai, Y et al : Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension : a single-center cohort. Rheumatology (Oxford) 51 : 1846-1854, 2012
 
2) Frost, A et al : Diagnosis of pulmonary hypertension. Eur Respir J 53 : 1801904, 2019
PubMed
3) Weatherald, J et al : Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 28 : 190023, 2019
PubMed
4) Coghlan, JG et al : Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis : the DETECT study. Ann Rheum Dis 73 : 1340-1349, 2014
PubMed
5) Fox, BD et al : High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 42 : 1083-1091, 2013
PubMed
6) Galie, N et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 : 67-119, 2016
 
7) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 
8) Yasuoka, H et al : Predictors for favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J 82 : 546-554, 2018
PubMed
9) Coghlan, JG et al : Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) : subgroup analysis from the AMBITION trial. Ann Rheum Dis 76 : 1219-1227, 2017
PubMed
P.526 掲載の参考文献
1) Kim, NH et al : Chronic thromboembolic pulmonary hypertension. Eur Respir J 53 : 1801915, 2019
PubMed
2) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf (2020年10月閲覧)
 
3) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 
4) Konstantinides, SV et al : 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism : The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) : Endorsed by the European Respiratory Society (ERS). Eur Heart J 35 : 3033-3069, 3069a-3069k, 2014
 
5) Jamieson, SW et al : Pulmonary endarterectomy : experience and lessons learned in 1,500 cases. Ann Thorac Surg 76 : 1457-1462 ; discussion 1462-1464, 2003
 
6) Pepke-Zaba, J et al : Chronic thromboembolic pulmonary hypertension (CTEPH) : results from an international prospective registry. Circulation 124 : 1973-1981, 2011
PubMed
7) Seki, T et al : Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism. Heart Vessels 13 : 195-198, 1998
 
8) Isshiki, I et al : Frequencies of prothrombin 20210 G-->A mutation may be different among races--studies on Japanese populations with various forms of thrombotic disorders and healthy subjects. Blood Coagul Fibrinolysis 9 : 105-106, 1998
 
9) Feinstein, JA et al : Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 103 : 10-13, 2001
PubMed
10) Mizoguchi, H et al : Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5 : 748-755, 2012
PubMed
11) Kataoka, M et al : Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5 : 756-762, 2012
PubMed
12) Fukui, S et al : Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 43 : 1394-1402, 2014
PubMed
13) Aoki, T et al : Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension : long-term effects and procedure-related complications. Eur Heart J 38 : 3152-3159, 2017
PubMed
14) Ogawa, A et al : Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension : results of a multicenter registry. Circ Cardiovasc Qual Outcomes 10 : e004029, 2017
PubMed
15) Ghofrani, HA et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369 : 319-329, 2013
PubMed
16) Simonneau, G et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension : a long-term extension study (CHEST-2). Eur Respir J 45 : 1293-1302, 2015
PubMed

第9章 成人先天性心疾患

P.531 掲載の参考文献
1) 日本循環器学会 : 成人先天性心疾患診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_ichida_h.pdf (2020年10月閲覧)
 
2) Niwa, K : Adults with congenital heart disease transition. Curr Opin Pediatr 27 : 576-580, 2015
PubMed
3) 日本循環器学会ほか : 先天性心疾患の成人への移行医療に関する提言. 第2版, 2019, http://www.j-circ.or.jp/topics/files/ACHD_Transition_Teigen_update.pdf (2020年10月閲覧)
 
4) Niwa, K et al : Survey of specialized tertiary care facilities for adults with congenital heart disease. Int J Cardiol 96 : 211-216, 2004
PubMed
5) Roos-Hesselink, JW et al : Outcome of pregnancy in patients with structural or ischemic heart disease : results of a registry of the European Society of Cardiology. Eur Heart J 34 : 657-665, 2013
 
6) 丹羽公一郎ほか : 成人期先天性心疾患患者の社会的自立と問題点. J Cardiol 39 : 259-266, 2002
 
7) Enomoto, J et al : Psychosocial factors influencing mental health in adults with congenital heart disease. Circ J 77 : 749-755, 2013
PubMed
8) Kuwabara, M et al : Liver cirrhosis and/or hepatocellular carcinoma occurring late after the Fontan procedure -A nationwide survey in Japan. Circ J 82 : 1155-1160, 2018
 
9) Perloff, JK : Cyanotic Congenital Heart Disease : A Multisystem Disorder. Congenital Heart Disease in Adults, 3rd ed, Perloff, JK et al eds, Saunders Elsevier, Philadelphia, 1265-1289, 2009
 
P.537 掲載の参考文献
1) Apitz, C et al : Tetralogy of Fallot. Lancet 374 : 1462-1471, 2009
PubMed
2) Nakazawa, M et al : Arrhythmias late after repair of tetralogy of fallot : a Japanese Multicenter Study. Circ J 68 : 126-130, 2004
PubMed
3) Niwa, K et al : Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. Circulation 106 : 1374-1378, 2002
PubMed
4) Gatzoulis, MA et al : Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot : a multicentre study. Lancet 356 : 975-981, 2000
PubMed
5) Stout, KK et al : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73 : e81-e192, 2019
 
6) Larsen, SH et al : Surgical and percutaneous pulmonary valve replacement in England over the past two decades. Heart 105 : 932-937, 2019
PubMed
7) Gatzoulis, MA et al : Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 92 : 231-237, 1995
PubMed
8) Valente, AM et al : Multimodality imaging guidelines for patients with repaired tetralogy of fallot : a report from the American Society of Echocardiography : developed in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society for Pediatric Radiology. J Am Soc Echocardiogr 27 : 111-141, 2014
 
9) Kogon, BE et al : Adult congenital pulmonary valve replacement : a simple, effective, and reproducible technique. Congenit Heart Dis 2 : 314-318, 2007
PubMed
10) McElhinney, DB et al : Endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol 72 : 2717-2728, 2018
PubMed
11) Pragt, H et al : Mechanical valves in the pulmonary position : An international retrospective analysis. J Thorac Cardiovasc Surg 154 : 1371-1378.e1, 2017
 
P.544 掲載の参考文献
1) Akagi, T : Current concept of transcatheter closure of atrial septal defect in adults. J Cardiol 65 : 17-25, 2015
PubMed
2) Baumgartner, H et al : ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) : The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC) : Endorsed by the Association for European Paediatric Cardiology (AEPC). Eur Heart J 31 : 2915-2957, 2010
 
3) Kijima, Y et al : Treat and repair strategy in patients with atrial septal defect and significant pulmonary arterial hypertension. Circ J 80 : 227-234, 2015
PubMed
4) Kijima, Y et al : Deficient surrounding rims in patients undergoing transcatheter atrial septal defect closure. J Am Soc Echocardiogr 29 : 768-776, 2016
PubMed
5) Takaya, Y et al : Long-term outcome after transcatheter closure of atrial septal defect in older patients : impact of age at procedure. JACC Cardiovasc Interv 8 : 600-606, 2015
PubMed
6) Amin, Z et al : Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects : review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 63 : 496-502, 2004
PubMed
7) Nakagawa, K et al : Efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with atrial septal defect : a comparison with transcatheter closure alone. Europace 21 : 1663-1669, 2019
PubMed
8) Carroll, JD et al : Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 368 : 1092-1100, 2013
PubMed
9) 日本脳卒中学会/日本循環器学会/日本心血管インターベンション学会 : 潜因性脳梗塞に対する経皮的卵円孔閉鎖術の手引き. 2019, https://www.jsts.gr.jp/img/tebiki_seninsei_noukousoku.pdf (2020年1月閲覧)
 
10) Ueno, Y et al : Paradoxical brain embolism may not be uncommon-prospective study in acute ischemic stroke. J Neurol 254 : 763-766, 2007
 
11) Saver, JL et al : Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377 : 1022-1032, 2017
PubMed
12) Sondergaard, L et al : Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 377 : 1033-1042, 2017
 
13) Nakayama, R et al : Identification of high-risk patent foramen ovale associated with cryptogenic stroke : development of a scoring system. J Am Soc Echocardiogr 32 : 811-816, 2019
PubMed
14) Mattle, HP et al : Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J 37 : 2029-2036, 2016
PubMed
P.549 掲載の参考文献
1) Hoffman, JI et al : The incidence of congenital heart disease. J Am Coll Cardiol 39 : 1890-1900, 2002
PubMed
2) Warnes, CA et al : Task force 1 : the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 37 : 1170-1175, 2001
 
3) Lopez, L et al : Classification of ventricular septal defects for the eleventh iteration of the international classification of diseases-striving for consensus : a report from the International Society for Nomenclature of Paediatric and Congenital Heart Disease. Ann Thorac Surg 106 : 1578-1589, 2018
PubMed
4) Kidd, L et al : Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 87 : I38-I51, 1993
PubMed
5) Neumayer, U et al : Small ventricular septal defects in adults. Eur Heart J 19 : 1573-1582, 1998
 
6) Moe, DG et al : Spontaneous closure of uncomplicated ventricular septal defect. Am J Cardiol 60 : 674-678, 1987
PubMed
7) Krovetz, LJ : Spontaneous closure of ventricular septal defect. Am J Cardiol 81 : 100-101, 1998
PubMed
8) Weidman, WH et al : Clinical course in adults with ventricular septal defect. Circulation 56 : I78-I79, 1977
PubMed
9) Gabriel, HM et al : Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol 39 : 1066-1071, 2002
 
10) Moller, JH et al : Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 68 : 1491-1497, 1991
PubMed
11) Roos-Hesselink, JW et al : Outcome of patients after surgical closure of ventricular septal defect at young age : longitudinal follow-up of 22-34 years. Eur Heart J 25 : 1057-1062, 2004
PubMed
12) Baumgartner, H et al : ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 31 : 2915-2957, 2010
PubMed
13) Bass, JL et al : Initial human experience with the Amplatzer perimembranous ventricular septal occluder device. Catheter Cardiovasc Interv 58 : 238-245, 2003
PubMed
14) Uebing, A et al : Pregnancy and congenital heart disease. BMJ 332 : 401-406, 2006
PubMed
P.552 掲載の参考文献
1) Wallis, GA et al : Congenitally corrected transposition. Orphanet J Rare Dis 6 : 22, 2011
PubMed
2) Kutty, S et al : Contemporary management and outcomes in congenitally corrected transposition of the great arteries. Heart 104 : 1148-1155, 2018
PubMed
3) Stout, KK et al : 2018 AHA/ACC guideline for the management of adults with congenital heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139 : e698-e800, 2019
 
4) Filippov, AA et al : Management of systemic right ventricular failure in patients with congenitally corrected transposition of the great arteries. Circulation 134 : 1293-1302, 2016
PubMed
5) Hofferberth, SC : Impact of pacing on systemic ventricular function in L-transposition of the great arteries. J Thorac Cardiovasc Surg 151 : 131-138, 2016
 
6) 日本循環器学会 : 成人先天性心疾患診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_ichida_h.pdf (2020年10月閲覧)
 
P.560 掲載の参考文献
1) d'Udekem, Y et al : Redefining expectations of long-term survival after the Fontan procedure : twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation 130 : S32-S38, 2014
 
2) Ohuchi, H : Where is the "optimal" Fontan hemodynamics? Korean Circ J 47 : 842-857, 2017
PubMed
3) Rychik, J et al : Evaluation and management of the child and adult with Fontan circulation : a scientific statement from the American Heart Association. Circulation 140 : e234-e284, 2019
 
4) Ben Ali W, et al : Extracardiac versus lateral tunnel Fontan : a meta-analysis of long-term results. Ann Thorac Surg 107 : 837-843, 2019
 
5) Ohuchi, H et al : Hemodynamic determinants of mortality after Fontan operation. Am Heart J 189 : 9-18, 2017
PubMed
6) Ohuchi, H et al : Determinants of aortic size and stiffness and the impact on exercise physiology in patients after the Fontan operation. Int Heart J 58 : 73-80, 2017
PubMed
7) Daniels, CJ et al : Fontan-associated liver disease : proceedings from the American College of Cardiology stakeholders meeting, October 1 to 2, 2015, Washington DC. J Am Coll Cardiol 70 : 3173-3194, 2017
 
8) Egbe, AC et al : Hepatocellular carcinoma after Fontan operation : multicenter case series. Circulation 138 : 746-748, 2018
PubMed
9) Ohuchi, H et al : Abnormal glucose metabolism in patients with Fontan circulation : Unique characteristics and associations with Fontan pathophysiology. Am Heart J 216 : 125-135, 2019
PubMed
P.564 掲載の参考文献
1) Makino, N et al : Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int 61 : 397-403, 2019
PubMed
2) 日本川崎病研究センター : 第24回川崎病全国調査成績. 2017, https://www.jichi.ac.jp/dph/wp-dph/wp-content/uploads/2020/09/mcls24report-1.pdf (2020年1月閲覧)
 
3) 日本川崎病学会ほか : 川崎病診断の手引き 改訂第6版. 2019, http://www.jskd.jp/info/pdf/tebiki201906.pdf (2020年1月閲覧)
 
4) 日本川崎病学会 : 冠動脈瘤の心エコー図. 症例写真, http://www.jskd.jp/info/photo.html (2020年1月閲覧)
 
5) Kobayashi, T et al : A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population. J Am Soc Echocardiogr 29 : 794-801.e29, 2016
 
6) Miura, M et al : Association of severity of coronary artery aneurysms in patients with Kawasaki disease and risk of later coronary events. JAMA Pediatr 172 : e180030, 2018
PubMed
7) 日本小児循環器学会 : 日本小児循環器学会 川崎病急性期治療のガイドライン (2020年改訂版). 日小児循環器会誌 36 : S1.1-S1.29, 2020, http://jpccs.jp/10.9794/jspccs.36.S1.1/data/index.pdf (2020年11月閲覧)
 
8) Kobayashi, T et al : Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113 : 2606-2612, 2006
PubMed
9) Kobayashi, T et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoint trial. Lancet 379 : 1613-1620, 2012
PubMed
10) Hamada, H et al : Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA) : a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 393 : 1128-1137, 2019
PubMed
P.569 掲載の参考文献
1) Mas, JL et al : Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377 : 1011-1021, 2017
 
2) Burlet, A et al : Renal function in cyanotic congenital heart disease. Nephron 81 : 296-300, 1999
PubMed
3) Niwa, K et al : Eisenmenger syndrome in adults : ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 34 : 223-232, 1999
PubMed
P.574 掲載の参考文献
1) Drenthen, W et al : Outcome of pregnancy in women with congenital heart disease : a literature review. J Am Coll Cardiol 49 : 2303-2311, 2007
PubMed
2) Isogai, T et al : Clinical features and peripartum outcomes in pregnant women with cardiac disease : a nationwide retrospective cohort study in Japan. Heart Vessels 33 : 918-930, 2018
PubMed
3) Ruys, TP et al : Heart failure in pregnant women with cardiac disease : data from the ROPAC. Heart 100 : 231-238, 2014
PubMed
4) 日本循環器学会/日本産科婦人科学会 : 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_akagi_ikeda.pdf (2020年10月閲覧)
 
5) Therrien, J et al : Canadian Cardiovascular Society Consensus Conference 2001 update : recommendations for the management of adults with congenital heart disease. Part I. Can J Cardiol 17 : 940-959, 2001
 
6) Therrien, J et al : Canadian Cardiovascular Society Consensus Conference 2001 update : recommendations for the management of adults with congenital heart disease. Part II. Can J Cardiol 17 : 1029-1050, 2001
 
7) Therrien, J et al : Canadian Cardiovascular Society Consensus Conference 2001 update : recommendations for the management of adults with congenital heart disease. Part III. Can J Cardiol 17 : 1135-1158, 2001
 
8) Canobbio, MM et al : Management of pregnancy in patients with complex congenital heart disease : a scientific statement for healthcare professionals from the American Heart Association. Circulation 135 : e50-e87, 2017
PubMed
9) Drenthen, W et al : Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 31 : 2124-2132, 2010
PubMed
10) Siu, SC et al : Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 104 : 515-521, 2001
PubMed
11) Silversides, CK et al : Pregnancy outcomes in women with heart disease : The CARPREG II Study. J Am Coll Cardiol 71 : 2419-2430, 2018
PubMed
12) Ohuchi, H et al : Cardiopulmonary variables during exercise predict pregnancy outcome in women with congenital heart disease. Circ J 77 : 470-476, 2013
PubMed
13) Regitz-Zagrosek, V et al : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy : The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 39 : 3165-3241, 2018
 

第10章 腫瘍循環器学

P.578 掲載の参考文献
1) Okura, Y et al : Future projection of cancer patients with cardiovascular disease in Japan by the year 2039 : a pilot study. Int J Clin Oncol 24 : 983-994, 2019
PubMed
2) Hermann, J et al : Building a cardio-onco-hematology program. Curr Oncol Rep 20 : 81, 2018
 
3) Yeh, ET et al : Cardiovascular complication of cancer therapy : incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 53 : 2231-2247, 2009
 
4) Yeh, ET : Onco-cardiology : the time has come. Tex Heart Inst J 38 : 246-247, 2011
PubMed
5) 向井幹夫 : がん診療における腫瘍循環器外来の役割. 医事新報 4631 : 48-49, 2013
Medical*Online
6) 日本臨床腫瘍学会編 : がん免疫療法ガイドライン, 第2版, 金原出版, 東京, 69-72, 2019
 
7) Mukai, M et al : Mechanism and management of cancer associated thrombosis. J Cardiol 72 : 89-93, 2018
PubMed
8) Mukai, M et al : Mechanism and management of cancer chemotherapy-induced atherosclerosis. J Atheroscler Thromb 25 : 994-1002, 2018
PubMed
9) Tilemann, LM et al : Cardio-oncology : conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 107 : 271-280, 2018
PubMed
10) Jaiswal, S et al : Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377 : 111-121, 2017
PubMed
11) Libby, P et al : Inflammation : a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology. Cardiovasc Res 115 : 824-829, 2019
PubMed
12) Dawson, MA et al : Cancer epigenetics : from mechanism to therapy. Cell 150 : 12-27, 2012
PubMed
13) 脳心血管病協議会 : 脳心血管病予防に関する包括的リスク管理チャート2019年版について. 日内会誌 108 : 1024-1070, 2019
 
14) Zamorano, JL et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
15) Albini, A et al : Cardiotoxicity of anticancer drugs : the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102 : 14-25, 2010
PubMed
16) Mulrooney, DA et al : Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer : retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339 : b4606, 2009
 
17) Chao, C et al : Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer : The Kaiser Permanente AYA Cancer Survivors Study. J Clin Oncol 34 : 1626-1633, 2016
 
18) Suter, TM et al : Cancer drugs and the heart : importance and management. Eur Heart J 34 : 1102-1111, 2013
PubMed
19) 向井幹夫 : がん関連血栓症とOnco-Cardiology. 日内会誌 109 : 1960-1967, 2020
 
P.585 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
2) Ewer, MS et al : Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12 : 547-558, 2015
PubMed
3) Renu, K et al : Molecular mechanism of doxorubicin-induced cardiomyopathy-An update. Eur J Pharmacol 818 : 241-253, 2018
PubMed
4) Sano, M et al : p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446 : 444-448, 2007
PubMed
5) Efentakis, P et al : Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood 133 : 710-723, 2019
PubMed
6) Johnson, DB et al : Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 : 1749-1755, 2016
PubMed
7) Ganatra, S et al : Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol 4 : 1491-1500, 2018
PubMed
8) Armenian, SH et al : Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017
 
9) Cardinale, D et al : Curing cancer, saving the heart : A challenge that cardioncology should not miss. Curr Cardiol Rep 18 : 51, 2016
 
10) Mahmood, SS et al : Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 : 1755-1764, 2018
PubMed
P.592 掲載の参考文献
1) Moslehi, JJ : Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 : 1457-1467, 2016
PubMed
2) Darby, SC et al : Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368 : 987-998, 2013
PubMed
3) Desai, MY et al : Prevention, diagnosis, and management of radiation-associated cardiac disease : JACC scientific expert panel. J Am Coll Cardiol 74 : 905-927, 2019
 
4) Reed, GW et al : Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv 9 : e003483, 2016
PubMed
5) de Jesus-Gonzalez, N et al : Management of antiangiogenic therapy-induced hypertension. Hypertension 60 : 607-615, 2012
PubMed
6) Versmissen, J et al : Vascular cardio-oncology : vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res 115 : 904-914, 2019
PubMed
7) Rini, BI et al : Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103 : 763-773, 2011
PubMed
8) Hall, PS et al : The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 1 : 72-78, 2013
 
9) Cortes, JE et al : Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the phase 2 PACE trial. Blood 132 : 393-404, 2018
PubMed
10) Nuver, J et al : Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23 : 9130-9137, 2005
PubMed
11) Cornell, RF et al : Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 37 : 1946-1955, 2019
PubMed
12) Hu, JR et al : Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115 : 854-868, 2019
PubMed
P.602 掲載の参考文献
1) Trousseau, A : Phlegmasia alba dolens. Clinique Medicale de L'hotel-dieu de Paris, 1865
 
2) Nakamura, M et al : Current venous thromboembolism management and outcomes in Japan. Circ J 78 : 708-717, 2014
PubMed
3) Yamashita, Y et al : Anticoagulation therapy for venous thromboembolism in the real world- from the COMMAND VTE Registry. Circ J 82 : 1262-1270, 2018
PubMed
4) Navi, BB et al : Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70 : 926-938, 2017
 
5) Asopa, S et al : Non-bacterial thrombotic endocarditis. Eur J Cardiothorac Surg 32 : 696-701, 2007
PubMed
6) Zamorano, JL et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
7) Abdol Razak, NB et al : Cancer-associated thrombosis : an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 10 : 380, 2018
 
8) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf (2020年10月閲覧)
 
9) Zhang, YY et al : Stroke risk factor, pattern and outcome in patients with cancer. Acta Neurol Scand 114 : 378-383, 2006
PubMed
10) Yusuf, SW et al : Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 35 : 443-450, 2012
PubMed
11) 野川茂 : がんと脳梗塞-トルーソー症候群の臨床. 血栓止血誌 27 : 18-28, 2016
 
12) Konstantinides, SV et al : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41 : 543-603, 2020
PubMed
13) Klok, FA et al : Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 48 : 1369-1376, 2016
PubMed
14) Khorana, AA et al : Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 : 4902-4907, 2008
PubMed
15) Carrier, M et al : Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380 : 711-719, 2019
PubMed
16) Khorana, AA et al : Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380 : 720-728, 2019
PubMed
17) Nam, KW et al : Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant. J Stroke Cerebrovasc Dis 26 : 2976-2980, 2017
PubMed
18) Gross, CM et al : Subacute coronary stent thrombosis in cancer patients. J Am Coll Cardiol 51 : 1232-1233, 2008
PubMed

第11章 生活習慣と心疾患

P.612 掲載の参考文献
1) Saeedi, P et al : Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045 : results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157 : 107843, 2019
PubMed
2) 中村二郎ほか : 糖尿病の死因に関する委員会報告-アンケート調査による日本人糖尿病の死因-2001-2010年の10年間, 45,708名での検討. 糖尿病 59 : 667-684, 2016
 
3) Cubbon, RM et al : Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 10 : 330-336, 2013
PubMed
4) MacDonald, MR et al : Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure : an analysis of the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 : 1377-1385, 2008
PubMed
5) Sakurai, M et al : HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population (NIPPON DATA 90). Diabetes Care 36 : 3759-3765, 2013
 
6) Hiro, T et al : Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome : a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54 : 293-302, 2009
PubMed
7) Stratton, IM et al : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ 321 : 405-412, 2000
PubMed
8) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 : 837-853, 1998
 
9) Holman, RR et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577-1589, 2008
PubMed
10) Patel, A et al : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 : 2560-2572, 2008
PubMed
11) Gerstein, HC et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
PubMed
12) Duckworth, W et al : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 : 129-139, 2009
PubMed
13) Hirsch, IB : Glycemic variability and diabetes complications : Does it matter? Of course it does! Diabetes Care 38 : 1610-1614, 2015
PubMed
14) Ueki, K et al : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5 : 951-964, 2017
 
15) Davies, MJ et al : Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61 : 2461-2498, 2018
 
16) Benjamin, EJ et al : Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 : 840-844, 1994
 
17) Huxley, RR et al : Type 2 diabetes, glucose homeostasis and incident atrial fibrillation : the Atherosclerosis Risk in Communities study. Heart 98 : 133-138, 2012
PubMed
18) Wang, A et al : Atrial fibrillation and diabetes mellitus : JACC review topic of the week. J Am Coll Cardiol 74 : 1107-1115, 2019
 
19) Du, X et al : Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation : results of the ADVANCE study. Eur Heart J 30 : 1128-1135, 2009
PubMed
20) Kannel, WB et al : Role of diabetes in congestive heart failure : the Framingham study. Am J Cardiol 34 : 29-34, 1974
PubMed
21) Nichols, GA et al : Congestive heart failure in type 2 diabetes : prevalence, incidence, and risk factors. Diabetes Care 24 : 1614-1619, 2001
PubMed
22) Ryden, L et al : ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD : The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 : 3035-3087, 2013
 
23) Sakakibara, M et al : Association of diabetes mellitus with myocardial collagen accumulation and relaxation impairment in patients with dilated cardiomyopathy. Diabetes Res Clin Pract 92 : 348-355, 2011
PubMed
24) Boudina, S et al : Diabetic cardiomyopathy revisited. Circulation 115 : 3213-3223, 2007
PubMed
25) Pereira, L et al : Mechanisms of [ Ca2+] i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55 : 608-615, 2006
PubMed
26) Boudina, S et al : Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112 : 2686-2695, 2005
PubMed
27) Fiordaliso, F et al : Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Invest 80 : 513-527, 2000
PubMed
28) Shigeta, T et al : Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126 : 1838-1851, 2012
PubMed
29) Zhou, YT et al : Lipotoxic heart disease in obese rats : implications for human obesity. Proc Natl Acad Sci U S A 97 : 1784-1789, 2000
PubMed
30) Tanaka, Y et al : Mitochondrial dysfunction observed in situ in cardiomyocytes of rats in experimental diabetes. Cardiovasc Res 26 : 409-414, 1992
PubMed
31) Cheung, N et al : Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 51 : 1573-1578, 2008
PubMed
32) Akasaka, T et al : Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol 30 : 935-941, 1997
PubMed
33) Aoyama, M et al : Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/Ras-related protein 1 axis. Circ Heart Fail 9 : e002081, 2016
PubMed
P.622 掲載の参考文献
1) Fujiyoshi, A et al : Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res 35 : 947-953, 2012
PubMed
2) 日本高血圧学会高血圧治療ガイドライン作成委員会編 : 高血圧治療ガイドライン 2019, 日本高血圧学会, 2019
 
3) Tozawa, M et al : Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41 : 1341-1345, 2003
PubMed
4) Ikeda, N et al : Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan : a comparative risk assessment. PLoS Med 9 : e1001160, 2012
PubMed
5) Kario, K et al : Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 38 : 238-245, 2001
PubMed
6) Sakima, A et al : Optimal blood pressure targets for patients with hypertension : a systematic review and meta-analysis. Hypertens Res 42 : 483-495, 2019
PubMed
7) Lewington, S et al : Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 : 1903-1913, 2002
PubMed
8) Wright, JT Jr et al : A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 : 2103-2116, 2015
PubMed
9) Verdecchia, P et al : Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis) : an open-label randomised trial. Lancet 374 : 525-533, 2009
PubMed
10) Kandzari, DE et al : Effect of renal denervation on blood pressure in the presence of antihypertensive drugs : 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391 : 2346-2355, 2018
PubMed
P.634 掲載の参考文献
1) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防のための脂質異常症診療ガイド 2018年版. 日本動脈硬化学会, 2018
Medical*Online
2) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防ガイドライン 2017年版. 日本動脈硬化学会, 2017
 
3) Rosensen, RS : Statins : can the new generation make an impression? Expert Opin Emerg Drugs 9 : 269-279, 2004
 
4) LaRosa, JC et al : Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425-1435, 2005
PubMed
5) Varbo, A et al : Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61 : 427-436, 2013
PubMed
6) 脳心血管病協議会 : 脳心血管病予防に関する包括的リスク管理チャート2019年版について. 日内会誌 108 : 1024-1074, 2019
 
7) Ghebreyesus, TA et al : REPLACE : a roadmap to make the world trans fat free by 2023. Lancet 391 : 1978-1980, 2018
PubMed
8) Cannon, CP et al : Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 : 2387-2397, 2015
PubMed
9) Yokoyama, M et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007
PubMed
10) Sabatine, MS et al : Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 : 1713-1722, 2017
PubMed
P.640 掲載の参考文献
1) 横山徹爾 : 循環器疾患・糖尿病予防対策における食の課題と今後の方向性. 保健医療科 66 : 582-589, 2017
 
2) 日本心不全学会 : 心不全患者における栄養評価・管理に関するステートメント. 2018, http://www.asas.or.jp/jhfs/pdf/statement20181012.pdf (2020年1月閲覧)
 
3) 厚生労働省 : 日本人の食事摂取基準 (2020年版) 「日本人の食事摂取基準」策定検討会報告書. 2019, https://www.mhlw.go.jp/content/10904750/000586553.pdf (2020年1月閲覧)
 
4) 伊藤 浩 : [1] -1. beyond LDL. なぜ今脂肪酸? そうだったんだ! 脂肪酸-循環器疾患との深い関係-, 伊藤浩編, 文光堂, 東京, 2-9, 2013
 
5) 島田和典ほか : 心血管イベント発症予防のためのNext Step-油と脂と脂肪酸を再考する-. 高崎医 68 : 38-42, 2018
 
6) Yanagisawa, N et al : Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Tromb 17 : 285-294, 2010
 
7) Kobayashi, S et al : Both comprehensive and brief self-administered diet history questionnaires satisfactorily rank nutrient intakes in Japanese adults. J Epidemiol 22 : 151-159, 2012
PubMed
8) Tsugane, S et al : Alcohol consumption and all-cause and cancer mortality among middle-aged Japanese men : seven-year follow-up of the JPHC study Cohort I. Japan Public Health Center. Am J Epidemiol 150 : 1201-1207, 1999
PubMed
9) O'Keefe, JH et al : Alcohol and cardiovascular health : the dose makes the poison…or the remedy. Mayo Clin Proc 89 : 382-393, 2014
 
10) Voskoboinik, A : Alcohol and atrial fibrillation : a sobering review. J Am Coll Cardiol 68 : 2567-2576, 2016
PubMed
11) 手嶋登志子 : 高齢者のQOLを高める食介護論 口から食べるしあわせ, 日本医療企画, 東京, 2006
 
P.646 掲載の参考文献
1) Fletcher, GF et al : Statement on exercise. benefits and recommendations for physical activity programs for all Americans. a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 86 : 340-344, 1992
 
2) Inoue, M et al : Daily total physical activity level and premature death in men and women : results from a large-scale population-based cohort study in Japan (JPHC Study). Ann Epidemiol 18 : 522-530, 2008
PubMed
3) 内藤義彦 : 厚生労働省運動基準・指針の改定のための検討会資料 疾病予防および健康に対する身体活動・運動の効用と実効性に影響する要因. 2012, https://www.mhlw.go.jp/stf/shingi/2r9852000002q9dz-att/2r9852000002q9k7.pdf (2020年1月閲覧)
 
4) 国立がん研究センター : 科学的根拠に基づくがん予防 がんになるリスクを減らすために. がん情報サービス, https://ganjoho.jp/public/pre_scr/cause_prevention/evidence_based.html (2020年1月閲覧)
 
5) Mason, JE et al : Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 347 : 716-725, 2002
 
6) Mandsager, K et al : Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 1 : e183605, 2018
 
7) United States Department of Health and Human Services : Updated Physical Activity Guidelines for Americans Now Available. https://health.gov/news-archive/blog/2018/11/updated-physical-activity-guidelines-for-americans-nowavailable/index.html (2020年1月閲覧)
 
8) Sobue, T et al : Influence of left ventricular hypertrophy on left ventricular function during dynamic exercise in the presence or absence of coronary artery disease. J Am Coll Cardiol 25 : 91-98, 1995
PubMed
9) Otaka, N et al : Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res 123 : 1326-1338, 2018
PubMed
10) MSD Manuals (Known as the Merck Manuals in the US and Canada and the MSD Manuals in the rest of the world), edited by Robert Porter. Copyright 2021 by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc, Kenilworth, NJ. Available at http://www.msdmanuals.com/ja-jp/ (2020年1月閲覧)
 
P.652 掲載の参考文献
1) Wolf, PA et al : Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 259 : 1025-1029, 1988
PubMed
2) The Pooling Project Research Group : Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events : Final report of the pooling project. J Chron Dis 31 : 201-306, 1978
 
3) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告) 循環器領域における性差医療に関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2010tei.h.pdf (2020年10月閲覧)
 
4) Huxley, RR et al : Cigarette smoking as a risk factor for coronary heart disease in women compared with men : a systematic review and meta-analysis of prospective cohort studies. Lancet 378 : 1297-1305, 2011
 
5) 上島弘嗣 : 第31回日本循環器管理研究協議会総会記録 特別報告 : 1980年循環器疾患基礎調査の追跡研究 (NIPPON DATA). 日循協誌 31 : 231-237, 1997
 
6) Peto, R et al : Mortality from Smoking in Developed Countries, 1950-2000. Oxford University Press, Oxford, 1994
 
7) 禁煙推進学術ネットワーク. http://tobacco-control-researchnet.jp/ (2020年1月閲覧)
 
8) 村松茂登彦 : たばこの燃焼と煙成分の生成. Health Sci 11 : 21-28, 1995
 
9) Perkins, KA et al : The cardiovascular effects of nicotine during stress. Psychopharmacology (Berl) 90 : 373-378, 1986
PubMed
10) Allison, RD et al : Central and peripheral vascular effects during cigarette smoking. Arch Envioron Health 19 : 189-198, 1969
 
11) Iida, M et al : Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo. Stroke 29 : 1656-1665, 1998
PubMed
12) Cryer, PE et al : Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295 : 573-577, 1976
PubMed
13) Ohkubo, C : Some acute cardiopulmonary effects of mainstream and sidestream cigarette smoke in man. Prev Med 11 : 173-186, 1982
PubMed
14) 飯田稔ほか : わが国の循環器疾患の発生におよぼすHDLコレステロールの影響. 厚生の指標, 28 : 3, 1981
 
15) Mjos, OD : Lipid effects of smoking. Am Heart J 115 : 272-275, 1988
PubMed
16) Murohara, T et al : Cigarette smoke extract contracts isolated porcine coronary arteries by superoxide anion-mediated degradation of EDRF. Am J Physiol 266 : H874-H880, 1994
PubMed
17) Celermajer, DS et al : Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88 : 2149-2155, 1993
PubMed
18) Kato, T et al : Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function. Hypertens Res 37 : 655-658, 2014
PubMed
19) Hill, JM et al : Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 : 593-600, 2003
PubMed
20) Kondo, T et al : Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 24 : 1442-1447, 2004
PubMed
21) Steenland, K : Passive smoking and the risk of heart disease. JAMA 267 : 94-99, 1992
PubMed
22) California Environmental Protection Agency : Health Effects of Exposure to Environmental Tobacco Smoke : Final Draft for Scientific, Public, and SRP Review. Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Sacramento, 1997
 
23) Jonas, MA et al : Statement on smoking and cardiovascular disease for health care professionals. American Heart Association. Circulation 86 : 1664-1669, 1992
PubMed
24) U.S. Department of Health and Human Services : 2006 Surgeon General's Report : The Health Consequences of Involuntary Exposure to Tobacco Smoke. Center for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, 2006
 
25) Meyers, DG et al : Cardiovascular effect of bans on smoking in public places : a systematic review and meta-analysis. J Am Coll Cardiol 54 : 1249-1255, 2009
PubMed
26) Lightwood, JM et al : Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 120 : 1373-1379, 2009
PubMed
27) Pell, JP et al : Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 359 : 482-491, 2008
PubMed
28) 日本循環器学会 : 虚血性心疾患の一次予防ガイドライン (2012年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2012_shimamoto_h.pdf (2020年10月閲覧)
 
29) Kato, T et al Short-term passive smoking causes endothelial dysfunction via oxidative stress in nonsmokers Can J Physiol Pharmacol 84 : 523-529, 2006
PubMed
30) 日本循環器学会/日本肺癌学会/日本癌学会/日本呼吸器学会 : 禁煙治療のための標準手順書. 第7版, 2020, http://www.j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev7.pdf (2020年10月閲覧)
 
31) Hartmann-Boyce, J et al : Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 5 : CD000146, 2018
PubMed
32) Cahill, K et al : Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016 : CD006103, 2016
PubMed
33) Nakamura, M et al : Efficacy and tolerability of valenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 29 : 1040-1056, 2007
 
34) 中村正和 : 虚血性心疾患患者の禁煙指導. 心臓 33 : 615-617, 2001
Medical*Online
35) 原和夫 : 地域の連携による禁煙治療プロトコール -笠間モデルの構築-. 調剤と情報 23 (16) : 22-26, 2017
 
P.656 掲載の参考文献
1) Tominaga, M et al : Association between plasma B-type natriuretic peptide and anaemia in heart failure with or without ischaemic heart disease : a retrospective study. BMJ Open 9 : e024194, 2019
PubMed
2) Anand, IS et al : Anemia and iron deficiency in heart failure : current concepts and emerging therapies. Circulation 138 : 80-98, 2018
PubMed
3) Rocha, BML et al : The burden of iron deficiency in heart failure : therapeutic approach. J Am Coll Cardiol 71 : 782-793, 2018
PubMed
4) 厚生労働省 : 血液製剤の使用指針 (平成31年3月改正). https://www.mhlw.go.jp/content/11127000/000493546.pdf (2020年1月閲覧)
 
5) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
6) Silverberg, DS et al : The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4 : 681-686, 2002
PubMed
7) 日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2018. https://cdn.jsn.or.jp/data/CKD2018.pdf (2020年1月閲覧)
 
8) Rangaswami, J et al : Cardiorenal syndrome : classification, pathophysiology, diagnosis, and treatment strategies : a scientific statement from the American Heart Association. Circulation 139 : e840-e878, 2019
PubMed
9) Swedberg, K et al : Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 : 1210-1219, 2013
PubMed
10) Lewis, GD et al : Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency : the IRONOUT HF randomized clinical trial. JAMA 317 : 1958-1966, 2017
PubMed
11) Ponikowski, P et al : Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 : 657-668, 2014
PubMed
P.662 掲載の参考文献
1) 日本心臓リハビリテーション学会 : 心臓リハビリテーションの定義. 日本心臓リハビリテーション学会ステートメント, http://www.jacr.jp/web/about/statement/ (2020年1月閲覧)
 
2) 日本循環器学会 : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2012/11/JCS2012_Nohara.pdf (2020年10月閲覧)
 
3) O'Connor, GT et al : An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 80 : 234-244, 1989
 
4) Ornish, D et al : Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280 : 2001-2007, 1998
PubMed
5) La Rovere, MT et al : Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction. Circulation 106 : 945-949, 2002
PubMed
6) Hambrecht, R et al : Effect of exercise on coronary endothelial function in patients with coronary artery disease. New Engl J Med 342 : 454-460, 2000
PubMed
7) Adams, V et al : Impact of regular physical activity on the NAD (P) H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 111 : 555-562, 2005
PubMed
8) 石原俊一ほか : 心臓リハビリテーション患者の心理・社会的特徴について. 心臓リハ 3 : 22-26, 1998
Medical*Online
9) 高橋哲也 : 運動療法の適応と禁忌. -指導士認定試験準拠-心臓リハビリテーション必携, 日本心臓リハビリテーション学会編, 222, 2010
 
10) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 

第12章 特定患者の心疾患

P.670 掲載の参考文献
1) Bohm, M et al : Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). Am J Cardiol 116 : 1890-1897, 2015
PubMed
2) Gorodeski, EZ et al : Domain management approach to heart failure in the geriatric patient : present and future. J Am Coll Cardiol 71 : 1921-1936, 2018
PubMed
3) 日本心不全学会 : 高齢心不全患者の治療に関するステートメント. 2016, http://www.asas.or.jp/jhfs/pdf/Statement_HeartFailurel.pdf (2020年10月閲覧)
 
4) Hamaguchi, S et al : Body mass index is an independent predictor of long-term outcomes in patients hospitalized with heart failure in Japan. Circ J 74 : 2605-2611, 2010
PubMed
5) 日本心不全学会 : 心不全患者における栄養評価・管理に関するステートメント. 2018, http://www.asas.or.jp/jhfs/pdf/statement20181012.pdf (2020年10月閲覧)
 
6) Chen, LK et al : Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15 : 95-101, 2014
 
7) 荒井秀典 : フレイルの意義. 日老医誌 51 : 497-501, 2014
 
8) Yamada, M et al : Predictive value of frailty scores for healthy life expectancy in community-dwelling older Japanese adults. J Am Med Dir Assoc 16 : 1002.e7-1002.e11, 2015
 
9) Evans, WJ et al : Cachexia : a new definition. Clin Nutr 27 : 793-799, 2008
PubMed
10) Pasini, E et al : Amino acids : chemistry and metabolism in normal and hypercatabolic states. Am J Cardiol 93 : 3A-5A, 2004
PubMed
11) Pasini, E et al : Hypercatabolic syndrome : molecular basis and effects of nutritional supplements with amino acids. Am J Cardiol 101 : 11E-15E, 2008
PubMed
12) Tsuji, S et al : Nutritional status of outpatients with chronic stable heart failure based on serum amino acid concentration. J Cardiol 72 : 458-465, 2018
PubMed
13) Mozaffarian, D : Dietary and policy priorities for cardiovascular disease, diabetes, and obesity : a comprehensive review. Circulation 133 : 187-225, 2016
PubMed
14) Gomes, F et al : ESPEN guidelines on nutritional support for polymorbid internal medicine patients. Clin Nutr 37 : 336-353, 2018
PubMed
15) Krishnaswami, A et al : Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol 73 : 2584-2595, 2019
PubMed
16) 日本老年医学会 日本医療研究開発機構研究費・高齢者の薬物治療の安全性に関する研究研究班 : 高齢者の安全な薬物療法ガイドライン 2015, メジカルビュー社, 東京, 26-31, 2015
 
17) Halliday, BP et al : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF) : an open-label, pilot, randomised trial. Lancet 393 : 61-73, 2019
PubMed
P.673 掲載の参考文献
1) 日本循環器学会/日本産科婦人科学会 : 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_akagi_ikeda.pdf (2020年10月閲覧)
 
2) Jonson, M et al : Cardiovascular changes in normal pregnancy. Heart Disease and Pregnancy, 2nd ed, Steer, PJ et al eds, Cambridge University Press, Cambridge, 19-28, 2016
 
3) Zentner, D et al : Fertility and pregnancy in the Fontan population. Int J Cardiol 208 : 97-101, 2016
PubMed
4) Canobbio, MM et al : Management of pregnancy in patients with complex congenital heart disease : a scientific statement for healthcare professionals from the American Heart Association. Circulation 135 : e50-e87, 2017
PubMed
5) Robson, SC et al : Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 256 : H1060-H1065, 1989
PubMed
6) Siu, SC et al : Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation 105 : 2179-2184, 2002
PubMed
7) Hrycyk, J et al : Mode of delivery and pregnancy outcome in women with congenital heart disease. PLoS One 11 : e0167820, 2016
PubMed
P.684 掲載の参考文献
1) Kristensen, SD et al : New ESC/ESA Guidelines on non-cardiac surgery : cardiovascular assessment and management. Eur Heart J 35 : 2383-2431, 2014
 
2) Kaluza, GL et al : Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 35 : 1288-1294, 2000
PubMed
3) McFalls, EO et al : Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 351 : 2795-2804, 2004
PubMed
4) Poldermans, D et al : A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery : the DECREASE-V Pilot Study. J Am Coll Cardiol 49 : 1763-1769, 2007
PubMed
5) Poldermans, D et al : The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 341 : 1789-1794, 1999
 
6) Devereaux, PJ et al : Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) : a randomised controlled trial. Lancet 371 : 1839-1847, 2008
 
7) Lindenauer, PK et al : Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353 : 349-361, 2005
PubMed
8) Bangalore, S et al : Perioperative beta blockers in patients having non-cardiac surgery : a meta-analysis. Lancet 372 : 1962-1976, 2008
PubMed
9) Bouri, S et al : Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery. Heart 100 : 456-464, 2014
 
10) London, MJ et al : Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA 309 : 1704-1713, 2013
 
11) Schouten, O et al : Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 361 : 980-989, 2009
PubMed
12) Tokushige, A et al : Incidence and outcome of surgical procedures after coronary bare-metal and drug-eluting stent implantation : a report from the CREDO-Kyoto PCI/CABG registry cohort-2. Circ Cardiovasc Interv 5 : 237-246, 2012
PubMed
13) Hawn, MT et al : Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 310 : 1462-1472, 2013
PubMed
14) Valgimigli, M et al : 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39 : 213-260, 2017
 
15) McFadden, EP et al : Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 : 1519-1521, 2004
PubMed
16) Tanaka, A et al : Unfractionated heparin during the interruption of antiplatelet therapy for non-cardiac surgery after drug-eluting stent implantation. Intern Med 55 : 333-337, 2016
PubMed
17) Albaladejo, P et al : Non-cardiac surgery in patients with coronary stents : the RECO study. Heart 97 : 1566-1572, 2011
PubMed
18) Kang, SH et al : Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents : a systematic review and Bayesian approach network meta-analysis. Eur Heart J 35 : 1147-1158, 2014
PubMed
19) 田邉健吾ほか : エベロリムス溶出性ステント留置後患者における, 抗血小板剤中止が必要な非心臓手術の際の心血管イベント : SKYTREE Registry最終報告. 第26回日本心血管インターベンション治療学会学術集会 CVIT 2017 KYOTO, 2017
 
20) Steffel, J et al : The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39 : 1330-1393, 2018
PubMed

第13章 他臓器疾患による心血管疾患

P.693 掲載の参考文献
1) 大塚文男編 : General Mindで攻める 総合内科で診る内分泌疾患, 中外医学社, 東京, 2020
 
2) 中澤博江 : 見逃されている甲状腺疾患による循環器異常-診断と治療の実際-. Medical Practice 26 : 134-139, 2009
Medical*Online
3) 小林さゆき : 甲状腺心. 成人病と生活習慣病 47 : 1253-1257, 2017
Medical*Online
4) 赤津拓彦ほか : 甲状腺疾患. 別冊日本臨牀 循環器症候群 IV, 18-21, 日本臨牀社, 1996
 
5) 日本甲状腺学会 : 甲状腺機能低下症の診断ガイドライン. 甲状腺疾患診断ガイドライン 2013, http://www.japanthyroid.jp/doctor/guideline/japanese.html (2020年1月閲覧) より)
 
6) 日本内分泌学会編 : 内分泌代謝科専門医研修ガイドブック, 診断と治療社, 東京, 2018
 
7) 日本内分泌学会 : 先端巨大症および下垂体性巨人症の診断と治療の手引き (平成30年度改訂). 間脳下垂体機能障害の診断と治療の手引き (平成30年度改訂), 日内分泌会誌 95 : 1-7, 2019, https://www.jstage.jst.go.jp/browse/endocrine/95/S.May/_contents/-char/ja (2020年1月閲覧)
 
8) 平田結喜緒 : Cushing症候群. 日内会誌 92 : 359-366, 2003
 
9) 洲之内尭ほか : 高血圧症に隠れた内分泌疾患を見逃さないためには. 診断と治療 106 : 1054-1058, 2018
Medical*Online
10) 日本内分泌学会/日本内分泌外科学会 : 日本内分泌学会臨床重要課題「わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント」. 日内分泌会誌 92, 2016
 
11) 大江秀美 : 甲状腺疾患診療実践マニュアル, 第4版, 百渓尚子ほか編, 文光堂, 東京, 101-103, 2016
 
12) 中澤博江 : 甲状腺ホルモン/不整脈を中心とした循環系への影響と治療方針. 日甲状腺会誌 3 : 100-104, 2012
 
13) Osuna, PM : Hyperthyroidism and the heart. Methodist Debakey Cardiovasc J 13 : 60-63, 2017
PubMed
14) 高橋裕 : 先端巨大症における高血圧と心血管リスク. 最新医学 71 : 965-968, 2016
Medical*Online
15) Hundemer, GL : Primary aldosteroinism : cardiovascular outcomes pre- and post-treatment. Curr Cardiol Rep 21 : 93, 2019
PubMed
P.699 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf (2020年10月閲覧)
 
2) Tasdemir, HA et al : Cardiorespiratory function in Duchenne and Becker muscular dystrophy. Turk J Pediatr 38 : 307-314, 1996
PubMed
3) Heymsfield, SB et al : Sequence of cardiac changes in Duchenne muscular dystrophy. Am Heart J 95 : 283-294, 1978
PubMed
4) Demachi, J et al : Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Disord 14 : 732-739, 2004
PubMed
5) El-Hattab, AW et al : Mitochondrial cardiomyopathies. Front Cardiovasc Med 3 : 25, 2016
PubMed
6) Finsterer, J et al : Cardiac manifestations of primary mitochondrial disorders. Int J Cardiol 177 : 754-763, 2014
PubMed
7) 永島正明ほか : 心臓超音波シリーズ 3 ミトコンドリア心筋症. 日大医誌 74 : 2-6, 2015
 
8) 厚生労働省難治性疾患克服研究事業特発性心筋症調査研究班 : 心筋症 : 診断の手引きとその解説, 北畠顕, 友池仁暢編, 2005
 
P.703 掲載の参考文献
1) 佐藤 光 : 多枝spasm により特異な左室造影〔つぼ型〕を示したstunned myocardium. 臨床からみた心筋細胞障害-虚血から心不全まで, 児玉和久ほか編, 科学評論社, 東京, 1990
 
2) Lyon, AR et al : Current state of knowledge on Takotsubo syndrome : a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 18 : 8-27, 2016
 
3) Madhavan, M et al : Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy) : insights into the clinical significance of B-type natriuretic peptide and troponin levels. Heart 95 : 1436-1441, 2009
PubMed
4) Kosuge, M et al : Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. J Am Coll Cardiol 55 : 2514-2516, 2010
PubMed
5) Owa, M et al : Emotional stress-induced 'ampulla cardiomyopathy' : discrepancy between the metabolic and sympathetic innervation imaging performed during the recovery course. Jpn Circ J 65 : 349-352, 2001
PubMed
6) Prasad, A et al : Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy) : a mimic of acute myocardial infarction. Am Heart J 155 : 408-417, 2008
 
7) Templin, C et al : Clinical features and outcomes of takotsubo (stress) cardiomyopathy. New Engl J Med 373 : 929-938, 2015
PubMed
8) 日本循環器学会 : 失神の診断・治療ガイドライン (2012年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2012_inoue_h.pdf (2020年10月閲覧)
 
9) Brignole, M et al : Pacemaker therapy in patients with neurally mediated syncope and documented asystole : Third International Study on Syncope of Uncertain Etiology (ISSUE-3) : a randomized trial. Circulation 125 : 2566-2571, 2012
 
10) Forleo, C et al : Head-up tilt testing for diagnosing vasovagal syncope : a meta-analysis. Int J Cardiol 168 : 27-35, 2013
PubMed
11) La Rovere, MT et al : Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351 : 478-484, 1998
PubMed
P.710 掲載の参考文献
1) 家子正裕 : 凝固反応の基礎-特にトロンビン, 凝固Xa因子の役割. VTEジャーナル 2 : 176-182, 2012
Medical*Online
2) Hoffman, M et al : Cellular interactions in haemostasis. Haemostasis 26 : 12-16, 1996
PubMed
3) Ieko, M et al : Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. J Intensive Care 4 : 19, 2016
 
4) 家子正裕 : 先天性アンチトロンビン, 先天性プロテインS, 先天性プロテインC欠損症. Principles and Practice血液・造血器・リンパ系 医学生・レジデントのための必修エッセンス. 千葉滋編, 文光堂, 東京, 369-375, 2015
 
5) 家子正裕 : 血栓・止血機構を解説する. 診断と治療 104 : 520-525, 2016
Medical*Online
6) 家子正裕 : 出血性素因・血栓性素因. 歯科のための内科学, 改訂第4版, 西田次郎ほか編, 南江堂, 東京, 305-326, 2018
 
7) 内藤澄悦ほか : 出血傾向の鑑別. 止血・血栓ハンドブック, 鈴木重統ほか編, 西村書店, 東京, 17-23, 2015
 
8) 家子正裕 : リンパ・血管の症状-点状出血・紫斑-. 症状から診る内科疾患, 渡辺純夫ほか編, メジカルビュー社, 東京, 403-408, 2005
 
9) 家子正裕 : 血栓性疾患における検査値異常とその意義. よくわかる血栓・止血異常の診療, 金倉譲編, 中山書店, 東京, 273-283, 2014
 
10) Miyakis, S et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006
 
P.717 掲載の参考文献
1) Go, AS et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296-1305, 2004
PubMed
2) Moroi, M et al : Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis : results from a cohort study in Japan. Am J Kidney Dis 61 : 466-475, 2013
PubMed
3) Perkovic, V et al : The relationship between proteinuria and coronary risk : a systematic review and meta-analysis. PloS Med 5 : e207, 2008
 
4) Ronco, C et al : Cardio-renal syndromes : report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 31 : 703-711, 2010
PubMed
5) Ronco, C et al : Cardiorenal syndrome. J Am Coll Cardiol 52 : 1527-1539, 2008
PubMed
6) 日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2018. https://cdn.jsn.or.jp/data/CKD2018.pdf (2020年1月閲覧)
 
7) Turakhia, MP et al : Chronic kidney disease and arrhythmias : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 39 : 2314-2325, 2018
PubMed
8) Vavilis, G et al : Kidney dysfunction and the risk of developing aortic stenosis. J Am Coll Cardiol 73 : 305-314, 2019
PubMed
9) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 日透析医学会誌 44 : 337-425, 2011, https://www.jsdt.or.jp/tools/file/download.cgi/615/血液透析患者における心血管合併症の評価と治療に関するガイドライン.pdf (2020年1月閲覧)
 
10) Saito, Y et al : Proteinuria and reduced estimated glomerular filtration rate are independent risk factors for contrast-induced nephropathy after cardiac catheterization. Circ J 79 : 1624-1630, 2015
PubMed

第14章 診察と検査

P.724 掲載の参考文献
1) Swartz, MH : Textbook of Physical Diagnosis, 6th ed, Saundars Elsevier, Philadelphia, 3-31, 2010
 
2) Constant, J : Bedside Cardiology, 5th ed, Lippincott Williams & Wilkins, Philadelphia, 1-15, 1999
 
P.733 掲載の参考文献
1) Blomstrom-Lundqvist, C et al : ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias -executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 108 : 1871-1909, 2003
 
2) Goldberger, AL et al : Golberger's Clinical Electrocardiography A simplified approach, 8th ed, Elsevier Saunders, Philadelphia, 2013
 
3) Rimmerman, CM : Electorcardiography Review A case-based approach, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2012
 
4) 森田宏 : 心電図. 循環器内科グリーンノート, 第2版, 伊藤浩編, 中外医学社, 東京, 20-29, 2018
 
P.745 掲載の参考文献
1) 日本循環器学会 : 循環器超音波検査の適応と判読ガイドライン (2010年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2010yoshida.h.pdf (2020年10月閲覧)
 
2) Lang, RM et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39.e14, 2015
 
3) Daimon, M et al : Normal values of echocardiographic parameters in relation to age in a healthy Japanese population : the JAMP study. Circ J 72 : 1859-1866, 2008
 
4) Nagueh, SF et al : Recommendations for the evaluation of left ventricular diastolic function by echocardiography. An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 29 : 277-314, 2016
PubMed
5) Daimon, M et al : Gender differences in age-related changes in left and right ventricular geometries and functions. Echocardiography of a healthy subject group. Circ J 75 : 2840-2846, 2011
PubMed
6) Baumgartner, H et al : Echocardiographic assessment of valve stenosis : EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 22 : 1-23, 2009
PubMed
7) Zoghbi, WA et al : Recommendations for noninvasive evaluation of native valvular regurgitation. A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30 : 303-371, 2017
 
8) 亀田徹ほか : Bラインを用いた point-of-care超音波による心原性肺水腫の評価. 超音波医 45 : 125-135, 2018
Medical*Online
P.752 掲載の参考文献
1) Lang, RM et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39.e14, 2015
 
2) Hiratzka, LF et al : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121 : e266-e369, 2010
 
3) Erbel, R et al : 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases : Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35 : 2873-2926, 2014
 
4) Boodhwani, M et al : Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. Can J Cardiol 30 : 577-589, 2014
 
5) Nishimura, RA et al : 2014 AHA/ACC Guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-e643, 2014
 
6) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
7) Vahanian, A et al : Guidelines on the management of valvular heart disease (version 2012) : the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 42 : S1-S44, 2012
 
8) 松尾汎ほか : 超音波による大動脈・末梢動脈病変の標準的評価法. 超音波医 41 : 405-414, 2014
 
9) 平井都始子ほか : 各血管別の正常像および画像のみかた. Medical Technology 25 : 451-470, 1997
 
10) Gerhard-Herman, M et al : Guidelines for noninvasive vascular laboratory testing : a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. Vasc Med 11 : 183-200, 2006
 
11) 日本超音波医学会/日本脈管学会/日本静脈学会 静脈エコー検討小委員会 : 超音波による深部静脈血栓症・下肢静脈瘤の標準的評価法. 静脈学 29 : 363-394, 2018
 
12) Konstantinides, SV et al : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism : The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) : Endorsed by the European Respiratory Society (ERS). Eur Heart J 35 : 3033-3369, 2014
 
13) Baldridge, ED et al : Clinical significance of free-floating venous thrombi. J Vasc Surg 11 : 62-69, 1990
PubMed
14) Bernardi, E et al : Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis : a randomized controlled trial. JAMA 300 : 1653-1659, 2008
PubMed
15) 松尾汎ほか : 超音波による腎動脈病変の標準的評価法. 超音波医 42 : 185-200, 2015
 
16) Ciccone, MM et al : The renal arterial resistance index : a marker of renal function with an independent and incremental role in predicting heart failure progression. Eur J Heart Fail 16 : 210-216, 2014
PubMed
17) Ennezat, PV et al : Renal resistance index and its prognostic significance in patients with heart failure with preserved ejection fraction. Nephrol Dial Transplant 26 : 3908-3913, 2011
PubMed
P.767 掲載の参考文献
1) 日本循環器学会 : 循環器疾患診療実態調査 2012年報告書 (2013年実施・公表). http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2012web.pdf (2020年10月閲覧)
 
2) 日本循環器学会 : 循環器疾患診療実態調査 2017年報告書 (2018年度実施・公表). http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2017web.pdf (2020年10月閲覧)
 
3) 日本循環器学会 : 循環器疾患診療実態調査 2018年報告書 (2019年実施・公表). http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2018web.pdf (2020年10月閲覧)
 
4) Schroeder, S et al : Cardiac computed tomography : indications, applications, limitations, and training requirements : report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J 29 : 531-556, 2008
 
5) 日本循環器学会 : 慢性冠動脈疾患診断ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_yamagishi_tamaki.pdf (2020年10月閲覧)
 
6) Wexler, L et al : Coronary artery calcification : pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 94 : 1175-1192, 1996
PubMed
7) Agatston, AS et al : Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15 : 827-832, 1990
PubMed
8) Nasir, K et al : Role of nonenhanced multidetector CT coronary artery calcium testing in asymptomatic and symptomatic individuals. Radiology 264 : 637-649, 2012
PubMed
9) Leipsic, J et al : SCCT guidelines for the interpretation and reporting of coronary CT angiography : a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr 8 : 342-358, 2014
 
10) Cury, RC et al : CAD-RADS (TM) Coronary Artery Disease-Reporting and Data System. An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI). Endorsed by the American College of Cardiology. J Cardiovasc Comput Tomogr 10 : 269-281, 2016
 
11) Schmitt, R et al : Congenital anomalies of the coronary arteries : imaging with contrast-enhanced, multidetector computed tomography. Eur Radiol 15 : 1110-1121, 2005
PubMed
12) Taylor, CA et al : Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve : scientific basis. J Am Coll Cardiol 61 : 2233-2241, 2013
PubMed
P.773 掲載の参考文献
1) Gould, KL et al : Effects of coronary stenoses on coronary flow reserve and resistance. Am J Cardiol 34 : 48-55, 1974
PubMed
2) Boden, WE et al : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007
 
3) Shaw, LJ et al : Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden : results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 : 1283-1291, 2008
 
4) Hachamovitch, R et al : Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 32 : 1012-1024, 2011
PubMed
5) Moroi, M et al : Coronary revascularization does not decrease cardiac events in patients with stable ischemic heart disease but might do in those who showed moderate to severe ischemia. Int J Cardiol 158 : 246-252, 2012
 
6) Tonio, PA et al : Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 : 213-224, 2009
 
7) De Bruyne, B et al : Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371 : 1208-1217, 2014
PubMed
8) Melikian, N et al : Fractional flow reverse and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC Intervetion 3 : 307-314, 2010
 
9) Tamaki, N et al : Value and limitation of stress thallium-201 single photon emission computed tomography : comparison with nitrogen-13 ammonia positron tomography. J Nucl Med 29 : 1181-1188, 1988
PubMed
10) Tamaki, N et al : Perspectives of quantitative assessment of myocardial blood flow. Clin Transl Imaging 6 : 321-327, 2018
 
11) Jaarsma, C et al : Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease : a meta-analysis. J Am Coll Cardiol 59 : 1719-1728, 2012
PubMed
12) Berman, DS et al : Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease : flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol 61 : 469-477, 2013
PubMed
13) Ziadi, MC et al : Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 58 : 740-748, 2011
PubMed
14) Taqueti, VR et al : Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation 131 : 528-535, 2015
PubMed
15) Tamaki, N et al : Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol 18 : 135-143, 2011
PubMed
16) Allman, KC : Noninvasive assessment myocardial viability : current status and future directions. J Nucl Cardiol 20 : 618-637, 2013
PubMed
17) Tamaki, N et al : Molecular imaging in heart failure patients. Clin Transl Imaging 1 : 341-351, 2013
 
18) Ohira, H et al : Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35 : 933-941, 2008
PubMed
19) Manabe, O et al : Multimodality evaluation of cardiac sarcoidosis. J Nucl Cardiol 19 : 621-624, 2012
 
20) Wolk, MJ et al : ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease. J Am Coll Cardiol 63 : 380-406, 2014
PubMed
21) 日本循環器学会 : 慢性冠動脈疾患診断ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_yamagishi_tamaki.pdf (2020年10月閲覧)
 
P.780 掲載の参考文献
1) Le, TT et al : Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn Reson 18 : 21, 2016
PubMed
2) Klem, I et al : Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage : an international, multicenter study. Circ Cardiovasc Imaging 4 : 610-619, 2011
PubMed
3) Becker, MAJ et al : The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy : a review and meta-analysis. JACC Cardiovasc Imaging 11 : 1274-1284, 2018
PubMed
4) Chan, RH et al : Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130 : 484-495, 2014
PubMed
5) Patel, MR et al : Detection of myocardial damage in patients with sarcoidosis. Circulation 120 : 1969-1977, 2009
PubMed
6) Yoon, YE et al : Prognostic value of coronary magnetic resonance angiography for prediction of cardiac events in patients with suspected coronary artery disease. J Am Coll Cardiol 60 : 2316-2322, 2012
PubMed
7) Feng, L et al : XD-GRASP : Golden-angle radial MRI with reconstruction of extra motion-state dimensions using compressed sensing. Magn Reson Med 75 : 775-788, 2016
PubMed
8) 日本循環器学会/日本心臓血管外科学会 : 安定冠動脈疾患の血行再建ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_nakamura_yaku.pdf (2020年10月閲覧)
 
9) Takx, RA et al : Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging 8 : e002666, 2015
PubMed
10) Nagel, E et al : Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380 : 2418-2428, 2019
 
11) Ugander, M et al : Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 33 : 1268-1278, 2012
PubMed
12) Roujol, S et al : Accuracy, precision, and reproducibility of four T1 mapping sequences : a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology 272 : 683-689, 2014
PubMed
13) Pica, S et al : Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 16 : 99, 2014
PubMed
14) Lurz, P et al : Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis : the Myo-Racer-Trial. J Am Coll Cardiol 67 : 1800-1811, 2016
 
15) Nakamori, S et al : Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging 11 : 48-59, 2018
PubMed
16) Lurz, JA et al : CMR-derived extracellular volume fraction as a marker for myocardial fibrosis : the importance of coexisting myocardial inflammation. JACC Cardiovasc Imaging 11 : 38-45, 2018
PubMed
17) Wong, TC et al : Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35 : 657-664, 2014
PubMed
18) Martinez-Naharro, A et al : Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 70 : 466-477, 2017
PubMed
19) Augustine, D et al : Global and regional left ventricular myocardial deformation measures by magnetic resonance feature tracking in healthy volunteers : comparison with tagging and relevance of gender. J Cardiovasc Magn Reson 15 : 8, 2013
 
20) Gong, IY et al : Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab : a longitudinal study. Int J Cardiovasc Imaging 35 : 653-662, 2019
PubMed
P.789 掲載の参考文献
1) 日本循環器学会 : 慢性冠動脈疾患診断ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_yamagishi_tamaki.pdf (2020年10月閲覧)
 
2) Coronary artery surgery study (CASS) : a randomized trial of coronary artery bypass surgery. Survival data. Circulation 68 : 939-950, 1983
 
3) Kennedy, JW : Complications associated with cardiac catherization and angiography. Cathet Cardiovasc Diagn 8 : 5-11, 1982
 
4) Gersh, BJ et al : Long-term (5 year) results of coronary bypass surgery in patients 65 years old or older : a report from the Coronary Artery Surgery Study. Circulation 68 : II190-II199, 1983
PubMed
5) 厚生労働省 : 重篤副作用疾患別対応マニュアル 非ステロイド性抗炎症薬による喘息発作 (アスピリン喘息, 解熱鎮痛薬喘息, アスピリン不耐喘息, 鎮痛剤喘息症候群). 2006, https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1b05.pdf (2020年1月閲覧)
 
6) Jolly, SS et al : Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events : a systemic review and meta-analysis or randomized trials. Am Heart J 157 : 132-140, 2009
 
7) Sueda, S : Overview of complications during pharmacological spasm provocation tests. J Caridol 68 : 1-6, 2016
 
P.795 掲載の参考文献
1) Kubo, T et al : Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial) : one-year angiographic and clinical results. Eur Heart J 38 : 3139-3147, 2017
PubMed
2) Saito, Y et al : Clinical expert consensus document on standards for measurements and assessment of intravascular ultrasound from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther 35 : 1-12, 2020
PubMed
3) Nijjer, SS et al : Coronary pressure and flow relationships in humans : phasic analysis of normal and pathological vessels and the implications for stenosis assessment : a report from the Iberian-Dutch-English (IDEAL) collaborators. Eur Heart J 37 : 2069-2080, 2016
PubMed
4) van de Hoef, TP et al : Fractional flow reserve and beyond. Heart 99 : 1699-1705, 2013
PubMed
5) Murthy, VL et al : Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 124 : 2215-2224, 2011
PubMed
6) Pijls, NH et al : Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 334 : 1703-1708, 1996
PubMed
7) Neumann, FJ et al : 2018 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) : Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 40 : 87-165, 2019
 
8) Davies, JE et al : Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 376 : 1824-1834, 2017
 
9) Van't Veer, M et al : Comparison of different diastolic resting indexes to iFR : Are they all equal? J Am Coll Cardiol 70 : 3088-3096, 2017
 
10) Svanerud, J et al : Validation of a novel non-hyperaemic index of coronary artery stenosis severity : the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention 14 : 806-814, 2018
PubMed
11) Ahn, JM et al : Fractional flow reserve and cardiac events in coronary artery disease : data from a prospective IRIS-FFR registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve). Circulation 135 : 2241-2251, 2017
PubMed
12) Escaned, J et al : Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease : 1-year results of the SYNTAX II study. Eur Heart J 38 : 3124-3134, 2017
PubMed
P.800 掲載の参考文献
1) Sakakibara, S et al : Endomyocardial biopsy. Jpn Heart J 3 : 537-543, 1962
PubMed
2) Cooper, LT et al : The role of endomyocardial biopsy in the management of cardiovascular disease : a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology : Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 28 : 3076-3093, 2007
 
3) Casella, M et al : Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. Circ Arrhythm Electrophysiol 8 : 625-632, 2015
PubMed
4) Kawakatsu, N et al : Isolated cardiac sarcoidosis diagnosed by electroanatomic voltage mapping-guided endomyocardial biopsy combined with magnetic resonance imaging and positron emission tomography. J Cardiol Cases 14 : 107-110, 2016
PubMed
5) 心筋生検研究会編 : 心筋生検の適応症・方法・合併症と対処法. 診断モダリティとしての心筋病理, 南江堂, 東京, 9-12, 2017
 
6) Hiramitsu, S et al : National survey of the use of endomyocardial biopsy in Japan. Jpn Circ J 62 : 909-912, 1998
PubMed
7) 日本循環器学会 : 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2020/02/JCS2009_izumi_h.pdf (2020年10月閲覧)
 
8) 日本循環器学会 : 循環器病ガイドラインシリーズ 2016年度版 心臓サルコイドーシスの診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_terasaki_h.pdf (2020年10月閲覧)
 
9) Uemura, A et al : Histologic diagnostic rate of cardiac sarcoidosis : evaluation of endomyocardial biopsies. Am Heart J 138 : 299-302, 1999
PubMed
P.806 掲載の参考文献
1) Kohzuki, M : New ideas on limitations to V4O2max : five major determinants for V4O2max. Pulm Res Respir Med Open J 5 : e1-e2, 2018
 
2) Antman, EM et al : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 : e82-292, 2004
 
3) 日本循環器学会 : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2012/11/JCS2012_Nohara.pdf (2020年10月閲覧)
 
4) 日本循環器学会 運動に関する診療基準委員会 : 運動療法に関する診療基準 (1989年度報告). Jpn Circ J 55 : 386-397, 1991
 
5) 前田知子 : 各種呼気ガス分析指標. 心臓リハビリテーション, 上月正博編, 医歯薬出版, 東京, 177-184, 2013
 
6) 上月正博 : フィットネス. リハビリテーションにおける評価 Ver.3, 上月正博ほか編, 医歯薬出版, 東京, 34-44, 2016
 
7) Bonow, RO Carabello BA, Chatterjee K, et al : ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48 : e1-e148, 2006
 
8) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2020年10月閲覧)
 
9) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf (2020年10月閲覧)
 

第15章 臨床研究を実施する

P.815 掲載の参考文献
1) 国立国際医療センター臨床研究研修コース編 : 初期臨床で身につけたい臨床研究のエッセンス, 改訂第2版, 国立国際医療センター, 2009
 
2) 日本医療機能評価機構 : Mindsガイドラインライブラリ. https://minds.jcqhc.or.jp/ (2020年1月閲覧)
 
3) 日本医療機能評価機構 : Minds診療ガイドライン作成マニュアル 2017. https://minds.jcqhc.or.jp/docs/minds/guideline/pdf/manual_all_2017.pdf (2020年1月閲覧)
 
4) 日本循環器学会 : 2020年JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf (2020年10月閲覧)
 
5) 山下武志 : リアルワールドデータの真っ赤な真実 宝の山か, ゴミの山か. 南江堂, 東京, 2017
 
6) 植田真一郎 : 論文を正しく読むのはけっこう難しい 診療に生かせる解釈のキホンとピットフォール. 医学書院, 東京, 2018
 

書評

最近チェックした商品履歴

Loading...